<div class="prescribing-wrapper">
    <div class="prescribing-info-box">
<svg id="desktop" xmlns="http://www.w3.org/2000/svg" width="784.5" height="7836" viewBox="0 0 784.5 7990">
  <g id="Group_21" data-name="Group 21" transform="translate(-485.75 -102)">
    <text id="column-1" data-name="These highlights do not include all the information needed to use AKLIEF® Cream safely and effectively. See full prescribing information for AKLIEF Cream. AKLIEF (trifarotene) cream, for topical use Initial U.S. Approval: 2019————-————-——INDICATIONS AND" transform="translate(336 134)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">These highlights do not include all the information needed to use</tspan>
        <tspan x="0" y="31">AKLIEF</tspan>
        <tspan y="31" font-size="9.333" baseline-shift="5.33279994943018">®</tspan>
        <tspan y="31" xml:space="preserve"> Cream safely and effectively. See full prescribing</tspan>
        <tspan x="0" y="50">information for AKLIEF Cream.</tspan>
        <tspan x="0" y="69">AKLIEF (trifarotene) cream, for topical use</tspan>
        <tspan x="0" y="88">Initial U.S. Approval: 2019</tspan>
        <tspan x="0" y="126"></tspan>
        <tspan x="0" y="145">————-————-——INDICATIONS AND USAGE——————————</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="183">AKLIEF Cream is a retinoid indicated for the topical treatment of</tspan>
            <tspan x="0" y="202">acne vulgaris in patients 9 years of age and older. (1)</tspan>
        </tspan>
        <tspan x="0" y="240"></tspan>
        <tspan x="0" y="259">—————-————DOSAGE AND ADMINISTRATION—————————</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="297" xml:space="preserve">•   For topical use only. Not for oral, ophthalmic or intravaginal </tspan>
            <tspan x="0" y="316">     use.</tspan>
            <tspan x="0" y="335" xml:space="preserve">•   Apply a thin layer of AKLIEF Cream to the affected areas of the</tspan>
            <tspan x="0" y="354" xml:space="preserve">     face and/or trunk once a day, in the evening, on clean and dry</tspan>
            <tspan x="0" y="373" xml:space="preserve">     skin. Avoid contact with the eyes, lips, paranasal creases, and</tspan>
            <tspan x="0" y="392" xml:space="preserve">     mucous membranes. (2)</tspan>
        </tspan>
    </text>
    <text id="HIGHLIGHTS_OF_PRESCRIBING_INFORMATION" data-name="HIGHLIGHTS OF PRESCRIBING INFORMATION" transform="translate(336 102)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="9.48" y="12">HIGHLIGHTS OF PRESCRIBING INFORMATION</tspan>
    </text>
    <text id="_-_WARNINGS_AND_PRECAUTIONS_-" data-name="——-———————WARNINGS AND PRECAUTIONS—————————-" transform="translate(833 102)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="50.07" y="12">——-———————WARNINGS AND PRECAUTIONS—————————-</tspan>
    </text>
    <text id="_Skin_irritation:_Erythema_scaling_dryness_and_stinging_burning_may_be_experienced_with_use_of_AKLIEF_Cream._Use_a_moisturizer_from_the_initiation_of_treatment_and_if_appropriate_reduce_the_frequency_of_application_of_AKLIEF_Crea" data-name="•   Skin irritation: Erythema, scaling, dryness, and stinging/burning may be experienced with use of AKLIEF Cream. Use a moisturizer  from the initiation of treatment, and, if appropriate, reduce the frequency of application of AKLIEF Crea" transform="translate(840 134)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="40" y="12" xml:space="preserve">•   Skin irritation: Erythema, scaling, dryness, and stinging/burning </tspan>
        <tspan x="38" y="32" xml:space="preserve">     may be experienced with use of AKLIEF Cream. Use a moisturizer</tspan>
        <tspan x="38" y="52" xml:space="preserve">     from the initiation of treatment, and, if appropriate, reduce the </tspan>
        <tspan x="38" y="72" xml:space="preserve">     frequency of application of AKLIEF Cream, suspend or</tspan>
        <tspan x="38" y="92" xml:space="preserve">     discontinue use. (5.1)</tspan>
        <tspan x="40" y="112" xml:space="preserve">•   Ultraviolet Light and Environmental Exposure: Minimize exposure</tspan>
        <tspan x="38" y="132" xml:space="preserve">     to sunlight and sunlamps. Use sunscreen and protective clothing</tspan>
        <tspan x="38" y="152" xml:space="preserve">     over treated areas when exposure cannot be avoided. (5.2)</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="38" y="209">—————-——————ADVERSE REACTIONS————————————</tspan>
        </tspan>
        <tspan x="38" y="235">Most common adverse reactions (incidence ≥ 1%) in patients treated  </tspan>
        <tspan x="38" y="258"> with AKLIEF Cream were application site irritation, application site</tspan>
        <tspan x="38" y="278">pruritus and sunburn (6).</tspan>
    </text>
    <text id="_1_INDICATIONS_AND_USAGE_2_DOSAGE_AND_ADMINISTRATION_3_DOSAGE_FORMS_AND_STRENGTHS_4_CONTRAINDICATIONS_5_WARNINGS_AND_PRECAUTIONS_5.1_Skin_Irritation_5.2_Ultraviolet_Light_and_Environmental_Exposure_6_ADVERSE_REACTIONS_6.1_Clinical_Trials_Experie" data-name="1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Skin Irritation 5.2 Ultraviolet Light and Environmental Exposure 6 ADVERSE REACTIONS 6.1 Clinical Trials Experie" transform="translate(336 653)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">1 INDICATIONS AND USAGE</tspan>
        <tspan x="0" y="31">2 DOSAGE AND ADMINISTRATION</tspan>
        <tspan x="0" y="50">3 DOSAGE FORMS AND STRENGTHS</tspan>
        <tspan x="0" y="69">4 CONTRAINDICATIONS</tspan>
        <tspan x="0" y="88">5 WARNINGS AND PRECAUTIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="107" xml:space="preserve">    5.1 Skin Irritation</tspan>
            <tspan x="0" y="126" xml:space="preserve">    5.2 Ultraviolet Light and Environmental Exposure</tspan>
        </tspan>
        <tspan x="0" y="145">6 ADVERSE REACTIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="164" xml:space="preserve">    6.1 Clinical Trials Experience</tspan>
        </tspan>
        <tspan x="0" y="183">7 DRUG INTERACTIONS</tspan>
        <tspan x="0" y="202">8 USE IN SPECIFIC POPULATIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="221" xml:space="preserve">    8.1 Pregnancy</tspan>
            <tspan x="0" y="240" xml:space="preserve">    8.2 Lactation</tspan>
            <tspan x="0" y="259" xml:space="preserve">    8.4 Pediatric Use</tspan>
            <tspan x="0" y="278" xml:space="preserve">    8.5 Geriatric Use</tspan>
        </tspan>
    </text>
    <text id="_11_DESCRIPTION_12_CLINICAL_PHARMACOLOGY_12.1_Mechanism_of_Action_12.2_Pharmacodynamics_12.3_Pharmacokinetics_13_NONCLINICAL_TOXICOLOGY_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_14_CLINICAL_STUDIES_16_HOW_SUPPLIED_STORAGE_AND" data-name="11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND" transform="translate(873 653)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">11 DESCRIPTION</tspan>
        <tspan x="0" y="31">12 CLINICAL PHARMACOLOGY</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="50" xml:space="preserve">    12.1 Mechanism of Action</tspan>
            <tspan x="0" y="69" xml:space="preserve">    12.2 Pharmacodynamics</tspan>
            <tspan x="0" y="88" xml:space="preserve">    12.3 Pharmacokinetics</tspan>
        </tspan>
        <tspan x="0" y="107">13 NONCLINICAL TOXICOLOGY</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="126" xml:space="preserve">    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </tspan>
        </tspan>
        <tspan x="0" y="145">14 CLINICAL STUDIES</tspan>
        <tspan x="0" y="164">16 HOW SUPPLIED/STORAGE AND HANDLING</tspan>
        <tspan x="0" y="183">17 PATIENT COUNSELING INFORMATION</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="202">*Sections or subsections omitted from the</tspan>
            <tspan x="0" y="221">full prescribing information are not listed.</tspan>
        </tspan>
    </text>
    <text id="_1_INDICATIONS_AND_USAGE_AKLIEF_Cream_is_a_retinoid_indicated_for_the_topical_treatment_of_acne_vulgaris_in_patients_9_years_of_age_and_older._2_DOSAGE_AND_ADMINISTRATION_Apply_a_thin_layer_of_AKLIEF_Cream_to_the_affected_areas_once_daily_in_" data-name="1   INDICATIONS AND USAGE AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. 2   DOSAGE AND ADMINISTRATION Apply a thin layer of AKLIEF Cream to the affected areas once daily, in " transform="translate(336 1006)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">1   INDICATIONS AND USAGE</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="31" xml:space="preserve">     AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.</tspan>
        </tspan>
        <tspan x="0" y="50" xml:space="preserve">2   DOSAGE AND ADMINISTRATION</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="69" xml:space="preserve">     Apply a thin layer of AKLIEF Cream to the affected areas once daily, in the evening, on clean and dry skin</tspan>
            <tspan x="0" y="88" xml:space="preserve">     •   One pump actuation should be enough to cover the face (i.e., forehead, cheeks, nose, and chin).</tspan>
            <tspan x="0" y="107" xml:space="preserve">     •   Two actuations of the pump should be enough to cover the upper trunk (i.e., reachable upper back, shoulders and chest). One</tspan>
            <tspan x="0" y="126" xml:space="preserve">          additional pump actuation may be used for middle and lower back if acne is present.</tspan>
            <tspan x="0" y="145">The use of a moisturizer is recommended as frequently as needed from the initiation of treatment.</tspan>
            <tspan x="0" y="164">Avoid contact with the eyes, lips, paranasal creases, mucous membranes.</tspan>
            <tspan x="0" y="183">AKLIEF Cream is for topical use only. Not for oral, ophthalmic, or intravaginal use.</tspan>
        </tspan>
        <tspan x="0" y="202" xml:space="preserve">3   DOSAGE FORMS AND STRENGTHS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="221" xml:space="preserve">     Cream: 0.005%. Each gram of AKLIEF Cream contains 50 mcg of trifarotene in a white cream.</tspan>
        </tspan>
        <tspan x="0" y="240" xml:space="preserve">4   CONTRAINDICATIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="259" xml:space="preserve">     None</tspan>
        </tspan>
        <tspan x="0" y="297" xml:space="preserve">5   WARNINGS AND PRECAUTIONS</tspan>
        <tspan x="0" y="316" xml:space="preserve">     5.1   Skin Irritation</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="335" xml:space="preserve">     Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Maximum severity of these reactions </tspan>
            <tspan x="0" y="354" xml:space="preserve">     typically occurred within the first 4 weeks of treatment, and severity decreased with continued use of the medication. Depending upon</tspan>
            <tspan x="0" y="373" xml:space="preserve">     the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of application of AKLIEF Cream, or</tspan>
            <tspan x="0" y="392" xml:space="preserve">     suspend use temporarily. If severe reactions persist the treatment may be discontinued.</tspan>
            <tspan x="0" y="411" xml:space="preserve">     Avoid application of AKLIEF Cream to cuts, abrasions, or eczematous or sunburned skin. Use of “waxing” as a depilatory method should </tspan>
            <tspan x="0" y="430" xml:space="preserve">     be avoided on skin treated with AKLIEF Cream.</tspan>
        </tspan>
        <tspan x="0" y="449" xml:space="preserve">     5.2   Ultraviolet Light and Environmental Exposure</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="468" xml:space="preserve">     Minimize unprotected exposure to ultraviolet rays (including sunlight and sunlamps) during treatment with AKLIEF Cream. Warn patients </tspan>
            <tspan x="0" y="487" xml:space="preserve">     who normally experience high levels of sun exposure and those with inherent sensitivity to sun to exercise caution. Use of sunscreen </tspan>
            <tspan x="0" y="506" xml:space="preserve">     products and protective clothing over treated areas is recommended when exposure cannot be avoided.</tspan>
        </tspan>
        <tspan x="0" y="526" xml:space="preserve">6   Adverse Reactions</tspan>
        <tspan x="0" y="546" xml:space="preserve">     6.1   Clinical trial experience</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="568" xml:space="preserve">     Because clinical trials are conducted under widelyvarying conditions, adverse reaction rates observed in the clinical trials of a drug </tspan>
            <tspan x="0" y="588" xml:space="preserve">     cannot be directlycompared with rates in the clinical trials of another drug and may not reflect rates observed in practice. In the three </tspan>
            <tspan x="0" y="608" xml:space="preserve">     Phase 3 clinical trials, a total of 1673 subjects with acne vulgaris on the face and trunk, 9 years and older were exposed to AKLIEF Cream.</tspan>
            <tspan x="0" y="628" xml:space="preserve">     Of these, 1220 subjects were treated once dailyfor up to 12 weeks and 453 were treated once dailyfor up to 1year.</tspan>
            <tspan x="0" y="668" xml:space="preserve">     Adverse reactions reported in the 2randomized, double-blind,vehicle-controlled 12-weekclinical trials in ≥1.0% of subjects treated with</tspan>
            <tspan x="0" y="688" xml:space="preserve">     AKLIEF Cream (and for which the rate exceeded the rate forvehicle), as well as the corresponding rates reported in subjects treated with</tspan>
            <tspan x="0" y="708" xml:space="preserve">     the vehicle cream are presented in Table 1.</tspan>
        </tspan>
    </text>
    <text id="Additional_adverse_reactions_that_were_reported_in_more_than_one_subject_treated_with_AKLIEF_Cream_and_at_a_frequency_1_included_application_site_pain_application_site_dryness_application_site_discoloration_application_site_rash_application_site_sw" data-name="Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included application site pain, application site dryness, application site discoloration, application site rash, application site sw" transform="translate(336 1905)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included</tspan>
        <tspan x="0" y="31">application site pain, application site dryness, application site discoloration, application site rash, application site swelling, application site</tspan>
        <tspan x="0" y="50">erosion, acne, dermatitis allergic, and erythema.</tspan>
        <tspan x="0" y="69"></tspan>
        <tspan x="0" y="88">In the one-year, open-label safety trial that included 453 subjects 9 years and older, with acne vulgaris of the face and trunk, the pattern of </tspan>
        <tspan x="0" y="107">adverse reactions for AKLIEF Cream was similar to that experienced in the 12-week controlled trials. A total of 12.6% of subjects had at least </tspan>
        <tspan x="0" y="126">one adverse reaction during the trial, and 2.9% of subjects had an adverse reaction leading to treatment discontinuation. The most common</tspan>
        <tspan x="0" y="145">adverse reactions (≥ 1% of subjects) for the entire trial were application site pruritus (4.6%), application site irritation (4.2%), and sunburn</tspan>
        <tspan x="0" y="164">(5.5%). The frequency of adverse reactions decreased over time.</tspan>
        <tspan x="0" y="183"></tspan>
        <tspan x="0" y="202">Skin irritation was evaluated by active assessment of erythema, scaling, dryness, and stinging/burning and collected separately. In the two</tspan>
        <tspan x="0" y="221">12-week Phase 3 clinical trials, these signs/symptoms were assessed at baseline and at least one post-baseline visit, in 1214 subjects (for</tspan>
        <tspan x="0" y="240">face) and 1202subjects (for trunk) treated with AKLIEF Cream. The percentage of subjects who were assessed to have these signs and</tspan>
        <tspan x="0" y="259">symptoms at any post baseline visit and at a severity worse than baseline are summarized in Table 2.</tspan>

    </text>
    <text id="Local_tolerability_on_the_face_in_subjects_treated_with_AKLIEF_Cream_worsened_for_any_of_the_signs_symptoms_compared_with_baseline_to_a_score_of_moderate_for_up_to_30_of_subjects_or_severe_for_up_to_6_of_subjects._On_the_trunk_the_corresponding_percent" data-name="Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percent" transform="translate(336 2582)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptomscompared with baseline to a</tspan>
        <tspan x="0" y="31">score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percentages were up to 19%</tspan>
        <tspan x="0" y="50">(moderate) and up to 5% (severe). The scores reached maximum severity at Week 1 for the face, and at Week 2 to 4 of treatment for the trunk,</tspan>
        <tspan x="0" y="69">and decreased thereafter.</tspan>
        <tspan x="0" y="88">In the open-label, 1-year Phase 3 trial, the local tolerability profile was comparable to that observed in the two pivotal Phase 3 trials.</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="108" xml:space="preserve">7   DRUG INTERACTIONS</tspan>
        </tspan>
        <tspan x="0" y="128">Topical application of AKLIEF Cream is not expected to affect the circulating concentrations of oral hormonal contraceptives containing</tspan>
        <tspan x="0" y="148">ethinyl estradiol and levonorgestrel.</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="168" xml:space="preserve">8   USE IN SPECIFIC POPULATIONS</tspan>
        </tspan>
    </text>
    <text id="Available_data_from_clinical_trials_with_AKLIEF_Cream_use_in_pregnant_women_have_not_identified_a_drug-associated_risk_of_major_birth_defects_miscarriage_or_adverse_maternal_or_fetal_outcomes._There_are_case_reports_of_major_birth_defects_similar_to_thos" data-name="Available data from clinical trials with AKLIEF Cream use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  There are case reports of major birth defects similar to thos" transform="translate(352 2758)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="12" xml:space="preserve">8.1 Pregnancy</tspan>
        </tspan>
        <tspan text-decoration="underline">
            <tspan x="0" y="31">Risk Summary</tspan>
        </tspan>
        <tspan x="0" y="50">Available data from clinical trials with AKLIEF Cream use in pregnant women have not identified a drug-associated risk of major birth</tspan>
        <tspan x="0" y="69" xml:space="preserve">defects, miscarriage or adverse maternal or fetal outcomes. There are case reports of major birth defects similar to those seen in fetuses</tspan>
        <tspan x="0" y="88">exposed to oral retinoids in pregnant women exposed to other topical retinoids, but these case reports do not establish a pattern or </tspan>
        <tspan x="0" y="107">exposed to other topical retinoids, but these case reports do not establish a pattern or association with </tspan>
        <tspan x="0" y="126">association with retinoid-related embryopathy.</tspan>
        <tspan x="0" y="145">In animal reproduction studies, oral doses of trifarotene administered to pregnant rats and rabbits during organogenesis that resulted in</tspan>
        <tspan x="0" y="164">systemic exposures more than 800 times the systemic exposure at the maximum recommended human dose (MRHD) of AKLIEF Cream</tspan>
        <tspan x="0" y="183">resulted in adverse fetal eects, including fetal deaths and external,visceral, and skeletal malformations (see Data). The background risk of</tspan>
        <tspan x="0" y="202">major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or </tspan>
        <tspan x="0" y="221">other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically </tspan>
        <tspan x="0" y="240">recognized pregnancies is2% to 4% and 15% to 20%, respectively.</tspan>
        <tspan x="0" y="259">background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% </tspan>
        <tspan x="0" y="278">and 15% to 20%, respectively.</tspan>
        <tspan text-decoration="underline">
            <tspan x="0" y="297">Data</tspan>
        </tspan>
        <tspan font-family="Helvetica" font-weight="400" font-style="italic">
            <tspan x="0" y="316">Animal Data</tspan>
        </tspan>
        <tspan x="0" y="335">Oral administration of trifarotene to pregnant rats during the period of organogenesis at doses that resulted in systemic exposures greater </tspan>
        <tspan x="0" y="354">than 1600 times those in humans at the MRHD of AKLIEF Cream resulted in adverse fetal eects, including fetal deaths, reduced mean feta</tspan>
        <tspan x="0" y="373">weight, and external,visceral, and skeletal malformations. </tspan>
        <tspan x="0" y="392">Oral administration of trifarotene to pregnant rabbits during the period of organogenesis at doses that resulted in systemic exposures at</tspan>
        <tspan x="0" y="411">least 800 times those in humans at the MRHD of AKLIEF Cream resulted in adverse fetal eects, including defects of the tail, limbs, urogenital</tspan>
        <tspan x="0" y="430">organs, and vertebralcolumn. </tspan>
        <tspan x="0" y="449">Trifarotene administered orallyto female rats from gestation Day 6 to lactation Day20, at doses that resulted in systemic exposures up to</tspan>
        <tspan x="0" y="468">594 times those in humans at the MRHD of AKLIEF Cream, had no eect on maternal function or behavior, including gestation, delivery, pup-</tspan>
        <tspan x="0" y="487">rearing, lactation and nursing, orsurvival or development of pups. There were no eects of maternal treatment on behavior, learning,</tspan>
        <tspan x="0" y="506">memory, or reproductive function of pups. </tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="525" xml:space="preserve">8.2   Lactation</tspan>
        </tspan>
        <tspan text-decoration="underline">
            <tspan x="0" y="544">Risk Summary</tspan>
        </tspan>
        <tspan x="0" y="563">There are no data on the presence of trifarotene in human milk, the eects on the breastfed infant, or the eects on milk production. In </tspan>
        <tspan x="0" y="582">animal studies, trifarotene was present in rat milk with oral administration of the drug.When a drug is present in animal milk, it is likely that</tspan>
        <tspan x="0" y="601">the drug will be present in human milk. It is possible that topical administration of large amounts of trifarotene could result in sucient </tspan>
        <tspan x="0" y="620">systemic absorption to produce detectable quantities in human milk(see Clinical Considerations). The developmental and health benefits of </tspan>
        <tspan x="0" y="639">breastfeeding should be considered along with the mother’sclinical need for AKLIEF Cream and any potential adverse eects on the </tspan>
        <tspan x="0" y="658">breastfed infant fromAKLIEF Cream or from the underlying maternal condition. </tspan>
        <tspan x="0" y="677"> </tspan>
        <tspan x="0" y="696"></tspan>
        <tspan text-decoration="underline">
            <tspan x="0" y="677">Clinical Considerations</tspan>
        </tspan>
        <tspan x="0" y="696">To minimize potential exposure to the breastfed infantvia breastmilk, use AKLIEF Cream on the smallest area of skin and for the shortest </tspan>
        <tspan x="0" y="715">duration possible while breastfeeding. Advise breastfeeding women not to apply AKLIEF Cream directlyto the nipple and areola to avoid</tspan>
        <tspan x="0" y="734">direct infant exposure.</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="753" xml:space="preserve">8.4   Pediatric Use</tspan>
        </tspan>
        <tspan x="0" y="772">Safety and eectiveness of AKLIEF Cream for the topical treatment of acne vulgaris have been established in pediatric patients age 9 years</tspan>
        <tspan x="0" y="791">to 17years based on evidence from well-controlled clinical trials, long-term safetytrial, and a pharmacokinetictrial. A total of 897 pediatric</tspan>
        <tspan x="0" y="810">subjects aged 9 to 17years received AKLIEF Cream in the clinical trials [see Clinical Pharmacology(12.3) and Clinical Studies (14)].</tspan>
        <tspan x="0" y="829">Safety and eectiveness of AKLIEF Cream have not been established in pediatricsubjects under the age of 9 years.</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="848" xml:space="preserve">8.5 Geriatric use</tspan>
        </tspan>
        <tspan x="0" y="867">Clinical trials of AKLIEF Cream did not include anysubjects aged 65 years and over to determine whether they respond dierently than</tspan>
        <tspan x="0" y="886">younger subjects.</tspan>
    </text>
    <text id="_11_DESCRIPTION_AKLIEF_Cream_for_topical_administration_contains_0.005_50_mcg_g_trifarotene._Trifarotene_is_a_terphenyl_acid_derivative_and_is_a_retinoid._The_chemical_name_of_trifarotene_is_3_-tert-Butyl-4_-_2-hydroxy-ethoxy_-4_-pyrrolidin-1-yl-_1_1_3" data-name="11  DESCRIPTION AKLIEF Cream for topical administration contains 0.005% (50 mcg/g) trifarotene. Trifarotene is a terphenyl acid derivative and is a retinoid. The chemical name of trifarotene is 3”-tert-Butyl-4’-(2-hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3" transform="translate(336 3655)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">11  DESCRIPTION</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="31">AKLIEF Cream for topical administration contains 0.005% (50 mcg/g)</tspan>
            <tspan x="0" y="50">trifarotene. Trifarotene is a terphenyl acid derivative and is a </tspan>
            <tspan x="0" y="69">retinoid. The chemical name of trifarotene is 3”-tert-Butyl-4’-(2-</tspan>
            <tspan x="0" y="88">hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3’,1”]terphenyl-4-carboxylic</tspan>
            <tspan x="0" y="107">acid. Trifarotene has the molecular formula of C29H33NO4, the</tspan>
            <tspan x="0" y="126">molecular weight of 459.58, and the following structural formula:</tspan>
        </tspan>
    </text>
    <text id="Trifarotene_is_a_white_to_off-white_to_slightly_yellow_powder_with_the_melting_point_of_245_C._It_is_practically_insoluble_in_water_with_pKa1_of_5.69_and_pKa2_of_4.55._AKLIEF_trifarotene_Cream_0.005_contains_the_following_inactive_ingredients:_allantoin" data-name="Trifarotene is a white to off-white to slightly yellow powder with the melting point of 245°C. It is practically insoluble in water with pKa1 of 5.69 and pKa2 of 4.55. AKLIEF (trifarotene) Cream 0.005% contains the following inactive ingredients: allantoin" transform="translate(336 3797)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">Trifarotene is a white to o-white to slightly yellow powder with the melting point of 245°C. It is practicallyinsoluble in water with pKa1 of 5.69 </tspan>
        <tspan x="0" y="31">and pKa2 of 4.55. AKLIEF(trifarotene) Cream 0.005% contains the following inactive ingredients: allantoin,copolymer of acrylamide and </tspan>
        <tspan x="0" y="50">sodium acryloyldimethyltaurate, dispersion 40% in isohexadecane,cyclomethicone, 5% ethanol, medium-chain triglycerides,</tspan>
        <tspan x="0" y="69">phenoxyethanol, propylene glycol, purified water</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="88" xml:space="preserve">12  CLINICAL PHARMACOLOGY</tspan>
        </tspan>
    </text>
    <text id="_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_Trifarotene_was_not_carcinogenic_when_topically_applied_to_mice_daily_for_up_to_24_months_in_the_vehicle_of_the_product_AKLIEF_Cream_at_concentrations_of_0.0005_or_0.001_w_w._The_systemic_expo" data-name="13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility Trifarotene was not carcinogenic when topically applied to mice daily for up to 24 months in the vehicle of the product (AKLIEF Cream) at concentrations of 0.0005% or 0.001% w/w. The systemic expo" transform="translate(352 4565)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="33">Trifarotene was notcarcinogenic when topically applied to mice daily for up to 24 months in the vehicle of the product (AKLIEF Cream) at</tspan>
            <tspan x="0" y="52">concentrations of 0.0005% or 0.001% w/w. The systemic exposures at the highest doses evaluated in mice were approximately 82(males) and </tspan>
            <tspan x="0" y="71">99 (females) times higher than the human exposure at the MRHD of AKLIEF Cream </tspan>
            <tspan x="0" y="90">Trifarotene was notcarcinogenic when administered orally to rats daily for up to 24 months at doses up to 0.75 mg/kg/dayin males and 0.2</tspan>
            <tspan x="0" y="111">mg/kg/dayin females. The systemic exposures at the highest doses evaluated in rats were approximately 645 (males) and 1642 (females)</tspan>
            <tspan x="0" y="130">times higher than the human exposure at the MRHD of AKLIEF Cream. </tspan>
            <tspan x="0" y="149">Trifarotene was negative in an in vitro bacterial reverse mutation (Ames) assay, an in vitro micronucleus assayin primary human</tspan>
            <tspan x="0" y="168">lymphocytes, an in vitro mouse lymphoma assay with L5178Y/TK+/-cells, and an in vivo micronucleus assayin rats.</tspan>
            <tspan x="0" y="189">Trifarotene was assessed for eects on fertility or general reproductive function in rats. Males received trifarotene via oral gavage for 4 </tspan>
            <tspan x="0" y="208">weeks prior to mating, during mating, and up to scheduled termination (approximately 6 weeks in total), and females were treated via oral</tspan>
            <tspan x="0" y="227">gavage for 2 weeks prior to mating through Day 7 of gestation. No adverse effects on fertility or reproductive parameters, including sperm</tspan>
            <tspan x="0" y="248">motility and concentration, were observed at the highest doses evaluated, which resulted in systemic exposures approximately 1755 (males) </tspan>
            <tspan x="0" y="267">and 1726 (females) times higher than the human exposure at the MRHD of AKLIEF Cream. </tspan>
        </tspan>
    </text>
    <text id="_14_CLINICAL_STUDIES" data-name="14  CLINICAL STUDIES" transform="translate(336 4842)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">14  CLINICAL STUDIES</tspan>
    </text>
    <text id="AKLIEF_Cream_applied_once_daily_in_the_evening_was_evaluated_in_the_treatment_of_moderate_facial_and_truncal_acne_vulgaris_in_two_randomized_multicenter_parallel_group_double-blind_vehicle-controlled_trials_of_identical_design_Study_1_NCT02566369_an" data-name="AKLIEF Cream applied once daily in the evening was evaluated in the treatment of moderate facial and truncal acne vulgaris in two randomized, multicenter, parallel group, double-blind, vehicle-controlled trials of identical design, Study 1 (NCT02566369) an" transform="translate(352 4870)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">AKLIEF Cream applied once daily in the evening was evaluated in the treatment of moderate facial and truncal acne vulgaris in two </tspan>
        <tspan x="0" y="31">randomized, multicenter, parallel group, double-blind,vehicle-controlled trials of identical design, Study1 (NCT02566369) and Study 2</tspan>
        <tspan x="0" y="50">(NCT02556788). The trials were conducted in a total of 2420 subjects aged 9 years and older, who were treated for up to 12 weeks with either</tspan>
        <tspan x="0" y="69">AKLIEF Cream (1214 subjects) orvehicle cream (1206 subjects). Subjects were encouraged to use a moisturizer as desired, while allowing an </tspan>
        <tspan x="0" y="88">interval of approximately 1 hour before or after the studytreatment application.</tspan>
        <tspan x="0" y="107">Acne severity was evaluated using a 5-point Investigator’s Global Assessment (IGA) scale for the face and a 5-point Physician’s Global </tspan>
        <tspan x="0" y="126">Assessment (PGA) scale for the trunk with moderate acne vulgaris defined as a score of 3. Overall, 87% of subjects were Caucasian and 55%</tspan>
        <tspan x="0" y="147">were female. Thirty-four (1.4%) subjects were 9 to 11 years of age, 1128 (47%) subjects were 12 to 17 years of age, and 1258 (52%) subjects were</tspan>
        <tspan x="0" y="166">18 years and older. All subjects had moderate acne vulgaris on the face and 99% of subjects had moderate acne vulgaris on the trunk. At </tspan>
        <tspan x="0" y="185">baseline, subjects had between 7 and 200 (average 36) inflammatory lesions on the face and between 0 and 220 (average 38) on the trunk. </tspan>
        <tspan x="0" y="204">Additionally, subjects had 21 to 305 (average 52) non-inflammatory lesions on the face and 0 to 260 (average 46) on the trunk.</tspan>
        <tspan x="0" y="223">Success on the IGA/PGA scale was defined as achieving a score of 0 (clear) or 1 (almostclear) and at least a 2-grade improvement from </tspan>
        <tspan x="0" y="242">baseline. The co-primary endpoints (evaluated on the face) were the percentage of subjects achieving success on the IGA scale, the mean</tspan>
        <tspan x="0" y="261">absolute change in facial inflammatory lesion count from baseline, and the mean absolute change in facial non-inflammatory lesion count</tspan>
        <tspan x="0" y="280">from baseline, all evaluated atWeek12. The co-secondary endpoints (evaluated on the trunk) were the percentage of subjects achieving</tspan>
        <tspan x="0" y="301">success on the PGA scale, the mean absolute change in truncal inflammatory lesion count from baseline, and the mean absolute change in</tspan>
        <tspan x="0" y="320">truncal non-inflammatorylesion count from baseline, all evaluated atWeek12. Ecacyresults for acne on the face and trunk after 12 weeks</tspan>
        <tspan x="0" y="339">of treatment are presented in Tables 3 and 4 respectively.</tspan>
    </text>
    <text id="_13_NONCLINICAL_TOXICOLOGY" data-name="13  NONCLINICAL TOXICOLOGY" transform="translate(336 4545)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">13  NONCLINICAL </tspan>
    </text>
    <text id="_12.1_Mechanism_of_Action_Trifarotene_is_an_agonist_of_retinoic_acid_receptors_RAR_with_particular_activity_at_the_gamma_subtype_of_RAR._Stimulation_of_RAR_results_in_modulation_of_target_genes_which_are_associated_with_various_processes_including_cel" data-name="12.1   Mechanism of Action Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cel" transform="translate(352 3896)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">12.1   Mechanism of Action</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="31">Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results</tspan>
            <tspan x="0" y="50">in modulation of target genes which are associated with various processes, including cell dierentiation and mediation of inflammation.</tspan>
            <tspan x="0" y="69">The exact process by which trifarotene ameliorates acne is unknown.</tspan>
        </tspan>
        <tspan x="0" y="88" xml:space="preserve">12.2   Pharmacodynamics</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="107">At the approved recommended dosage, AKLIEF Cream does not prolong the QT interval to any clinically relevant extent.</tspan>
        </tspan>
        <tspan x="0" y="126" xml:space="preserve">12.3   Pharmacokinetics</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="145">Pharmacokinetics of trifarotene was evaluated in a studyinvolving 19 adult subjects with acne vulgaris following once daily application of </tspan>
            <tspan x="0" y="164">AKLIEF Cream for29 days (daily dose range 1.5 g/dayto 2 g/day) to the face, shoulders,chest and upper back. </tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300" text-decoration="underline">
            <tspan x="0" y="183">Absorption</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="202">Systemic concentrations were at steady state following 2 weeks of treatment and were quantifiable in 7subjects. Steady state Cmax </tspan>
            <tspan x="0" y="221">ranged from below the limit of quantification (less than 5 pg/mL) to 10 pg/mL and AUC0-24h ranged from 75 to 104 pg.h/mLin adults. No/</tspan>
            <tspan x="0" y="240">drug accumulation is expected with long-term use.</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300" text-decoration="underline">
            <tspan x="0" y="259">Distribution</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="278">Plasma protein binding is approximately 99.9%.</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300" text-decoration="underline">
            <tspan x="0" y="297">Elimination</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="316">The terminal half-life ranged from 2 to 9 hours.</tspan>
        </tspan>
        <tspan font-family="Helvetica" font-weight="400" font-style="italic">
            <tspan x="0" y="335">Metabolism</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="354">Trifarotene is primarily metabolized by CYP2C9, CYP3A4, CYP2C8, and to a lesser extent by CYP2B6 in vitro.</tspan>
        </tspan>
        <tspan font-family="Helvetica" font-weight="400" font-style="italic">
            <tspan x="0" y="373">Excretion</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="392">Trifarotene is primarily excreted by the feces.</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300" text-decoration="underline">
            <tspan x="0" y="411">Specific Populations</tspan>
        </tspan>
        <tspan font-family="Helvetica" font-weight="400" font-style="italic">
            <tspan x="0" y="430">Pediatric Patients</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="449">Steady state Cmax ranged from less than 5 pg/mLto 9 pg/mL and AUC0-24h ranged from 89 to 106 pg.h/mLin pediatrics (10 to 17-years-</tspan>
            <tspan x="0" y="468">old). Steadystate conditions were achieved in patients following 2 weeks of topical administration. No drug accumulation is expected </tspan>
            <tspan x="0" y="488">with long-term use.</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300" text-decoration="underline">
            <tspan x="0" y="507">Drug Interactions Studies</tspan>
        </tspan>
        <tspan font-family="Helvetica" font-weight="400" font-style="italic">
            <tspan x="0" y="526">Clinical Studies and Model-Based Approaches</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="545">No clinicallysignificant dierences in the pharmacokinetics of trifarotene were predicted when used concomitantly with fluconazole (a </tspan>
            <tspan x="0" y="564">moderate CYP2C9 and CYP3A inhibitor). </tspan>
        </tspan>
        <tspan font-family="Helvetica" font-style="italic">
            <tspan x="0" y="583">In Vitro Studies</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="602">Cytochrome P450 (CYP) Enzymes: AKLIEF Cream is not expected to inhibit CYP1A2,2B6,2C8,2C9,2C19,2D6 and 3A4, or induce CYP1A2,</tspan>
            <tspan x="0" y="621">2B6, and 3A4.</tspan>
            <tspan x="0" y="640">Transporter Systems: AKLIEF Cream is not expected to inhibit MATE, OATP, OAT, OCT, BCRP, P-gp, BSEP, or MPR</tspan>
        </tspan>
    </text>
    <text id="_16_HOW_SUPPLIED_STORAGE_AND_HANDLING" data-name="16  HOW SUPPLIED/STORAGE AND HANDLING" transform="translate(336 5926)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">16  HOW SUPPLIED/STORAGE AND HANDLING</tspan>
    </text>
    <text id="AKLIEF_Cream_0.005_is_provided_as_a_white_cream_supplied_in_the_following_packaging_configurations_with_corresponding_NDC_numbers:_30-gram_pump_NDC_0299-5935-30_45-gram_pump_NDC_0299-5935-45_75-gram_pump_NDC_0299-5935-75_Storage_and_Handling_" data-name="AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers: •   30-gram pump	NDC 0299-5935-30 •   45-gram pump	NDC 0299-5935-45 •   75-gram pump	NDC 0299-5935-75 Storage and Handling" transform="translate(352 5950)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers:</tspan>
        <tspan x="0" y="31" xml:space="preserve">•   30-gram pump	NDC 0299-5935-30</tspan>
        <tspan x="0" y="50" xml:space="preserve">•   45-gram pump	NDC 0299-5935-45</tspan>
        <tspan x="0" y="69" xml:space="preserve">•   75-gram pump	NDC 0299-5935-75</tspan>
        <tspan text-decoration="underline">
            <tspan x="0" y="88">Storage and Handling</tspan>
        </tspan>
        <tspan x="0" y="107">- Store at 20 to 25˚C (68 to 77˚F) with excursions permitted to 15°to 30°C (59° to 86°F).</tspan>
        <tspan x="0" y="126">- Keep away from heat.</tspan>
        <tspan x="0" y="145">- Keep out of reach of children.</tspan>
    </text>
    <text id="See_FDA-approved_patient_labeling_Patient_Information_._Advise_the_patient_to:_Cleanse_the_area_to_be_treated_pat_dry._Apply_AKLIEF_Cream_as_a_thin_layer_once_daily_in_the_evening_to_the_face_avoiding_the_eyes_lips_nasolabial_folds_and_m" data-name="See FDA-approved patient labeling (Patient Information). Advise the patient to:•   Cleanse the area to be treated; pat dry. Apply AKLIEF Cream as a thin layer once daily in the evening to the face, avoiding the eyes, lips,  nasolabial folds, and m" transform="translate(352 6129)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">See FDA-approved patient labeling (Patient Information).</tspan>
        <tspan x="0" y="31">Advise the patient to:</tspan>
        <tspan x="0" y="50" xml:space="preserve">•   Cleanse the area to be treated; pat dry. Apply AKLIEF Cream as a thin layer once daily in the evening to the face, avoiding the eyes, lips,</tspan>
        <tspan x="0" y="69" xml:space="preserve">    nasolabial folds, and mucous membranes. A thin layer of AKLIEF Cream may also be applied to the chest, shoulders, and back.</tspan>
        <tspan x="0" y="88" xml:space="preserve">•   Avoid applying AKLIEF Cream to damaged skin (such as cuts, abrasions), eczematous areas, and sunburned skin.</tspan>
        <tspan x="0" y="107" xml:space="preserve">•   Reduce the risk of such irritation, use a moisturizer from the start of treatment, and, if appropriate, reduce the frequency of application of</tspan>
        <tspan x="0" y="126" xml:space="preserve">     AKLIEF Cream or suspend use temporarily. AKLIEF Cream may cause irritation such as erythema, scaling, dryness, and stinging or </tspan>
        <tspan x="0" y="145" xml:space="preserve">     burning.</tspan>
        <tspan x="0" y="164" xml:space="preserve">•   Minimize exposure to sunlight, including sunlamps and phototherapy devices.</tspan>
         <tspan x="0" y="183" xml:space="preserve">•   Use sunscreen products and protective apparel (e.g., hat) over treated areas when exposure to sunlightcannot be avoided.</tspan>
        <tspan x="0" y="202" xml:space="preserve">•   Avoid concomitant use of other potentiallyirritating topical products (medicated or not). </tspan>
        <tspan x="0" y="221" xml:space="preserve">•   Use AKLIEF Cream on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women</tspan>
        <tspan x="0" y="240" xml:space="preserve">    not to apply AKLIEF Cream directlyto the nipple and areola to avoid direct infant exposure.</tspan>
    </text>
    <text id="Marketed_by:_GALDERMA_LABORATORIES_L.P._Fort_Worth_Texas_76177_USA_All_trademarks_are_the_property_of_their_respective_owners._Made_in_Canada_This_Patient_Information_has_been_approved_by_the_U.S._Food_and_Drug_Administration._Issued:_10_2019_P54485-" data-name="Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA All trademarks are the property of their respective owners. Made in Canada This Patient Information has been approved by the U.S. Food and Drug Administration.  Issued: 10/2019P54485-" transform="translate(352 6395)" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">Marketed by:</tspan>
        <tspan x="0" y="31">GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA</tspan>
        <tspan x="0" y="50">All trademarks are the property of their respective owners.</tspan>
        <tspan x="0" y="69">Made in Canada</tspan>
        <tspan x="0" y="88">All trademarks are the property of their respective owners.</tspan>
    </text>
    <text id="_17_PATIENT_COUNSELING_INFORMATION" data-name="17  PATIENT COUNSELING INFORMATION" transform="translate(336 6108)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">17  PATIENT COUNSELING INFORMATION</tspan>
    </text>
    <text id="FULL_PRESCRIBING_INFORMATION:_CONTENTS_" data-name="FULL PRESCRIBING INFORMATION: CONTENTS*" transform="translate(504 615)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="27.848" y="12">FULL PRESCRIBING INFORMATION: CONTENTS*</tspan>
    </text>
    <text id="FULL_PRESCRIBING_INFORMATION" data-name="FULL PRESCRIBING INFORMATION" transform="translate(504 981)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="79.848" y="12">FULL PRESCRIBING INFORMATION</tspan>
    </text>
    <g id="Group_15" data-name="Group 15">
        <g id="Group_1" data-name="Group 1" transform="translate(336 1785.623)">
            <rect id="Rectangle_1" data-name="Rectangle 1" width="985" height="107.721" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_1" data-name="Line 1" x2="985" transform="translate(0 80.791)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_2" data-name="Line 2" x2="985" transform="translate(0 53.861)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_3" data-name="Line 3" x2="985" transform="translate(0 26.93)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_4" data-name="Line 4" y2="107.721" transform="translate(706)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_5" data-name="Line 5" y2="107.721" transform="translate(355)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
        </g>
        <text id="Preferred_Term_Application_site_irritation_Application_site_pruritus_Sunburn" data-name="Preferred Term Application site irritation Application site pruritus Sunburn" transform="translate(430 1795.335)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="31.782" y="12">Preferred Term</tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="2.751" y="38">Application site irritation</tspan>
                <tspan x="4.087" y="64">Application site pruritus</tspan>
                <tspan x="58.175" y="90">Sunburn</tspan>
            </tspan>
        </text>
        <text id="AKLIEF_Cream_N_1220_91_7.5_29_2.4_32_2.6_" data-name="AKLIEF Cream (N= 1220) 91 (7.5) 29 (2.4) 32 (2.6)" transform="translate(760.548 1795.335)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="12">AKLIEF Cream (N=1220) </tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="61.658" y="38">91 (7.5)</tspan>
                <tspan x="61.658" y="64">29 (2.4)</tspan>
                <tspan x="61.658" y="90">32 (2.6)</tspan>
            </tspan>
        </text>
        <text id="Vehicle_Cream_N_1200_4_0.3_10_0.8_6_0.5_" data-name="Vehicle Cream (N=1200) 4 (0.3) 10 (0.8) 6 (0.5)" transform="translate(1085 1795.335)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="12">Vehicle Cream (N=1200)</tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="54.977" y="38">4 (0.3)</tspan>
                <tspan x="52.977" y="64">10 (0.8)</tspan>
                <tspan x="54.977" y="90">6 (0.5)</tspan>
            </tspan>
        </text>
        <text id="Table_1._Adverse_Reactions_Occurring_in_1.0_of_Subjects_with_Acne_Vulgaris_of_the_Face_and_Trunk_in_the_Two_12-week_Phase_3_Clinical_Trials" data-name="Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face and Trunk in the Two 12-week Phase 3 Clinical Trials" transform="translate(336 1735)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="12">Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face </tspan>
            <tspan x="0" y="31">and Trunk in the Two 12-week Phase 3 Clinical Trials</tspan>
        </text>
    </g>
    <text id="Table_2._Application_Site_Tolerability_Reactions_at_Any_Post_Baseline_Visit" data-name="Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit" transform="translate(336 2185.074)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700" letter-spacing="-0.01em">
        <tspan x="0" y="12">Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit</tspan>
    </text>
    <text id="Erythema_Scaling_Dryness_" data-name="Erythema Scaling Dryness" transform="translate(338 2293.477)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="10.959" y="12">Erythema</tspan>
        <tspan x="18.215" y="37">Scaling</tspan>
        <tspan x="15.407" y="62">Dryness</tspan>
    </text>
    <text id="Stinging_Burning" data-name="Stinging/Burning" transform="translate(338 2369.477)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="13.327" y="12">Stinging/</tspan>
        <tspan x="16.735" y="31">Burning</tspan>
    </text>
    <text id="Stinging_Burning-2" data-name="Stinging/Burning" transform="translate(338 2524.477)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="13.327" y="12">Stinging/</tspan>
        <tspan x="16.735" y="31">Burning</tspan>
    </text>
    <text id="AKLIEF_Cream_N_1214_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1214 Maximum Severity during Treatment" transform="translate(427.775 2223)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="75.682" y="12">AKLIEF Cream N=1214</tspan>
        <tspan x="24.342" y="31">Maximum Severity during Treatment</tspan>
    </text>
    <text id="Face" transform="translate(341.775 2230)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="23.428" y="12">Face</tspan>
    </text>
    <text id="Vehicle_Cream_N_1194_Maximum_Severity_during_Treatment_" data-name="Vehicle Cream N=1194 Maximum Severity during Treatment" transform="translate(808.675 2223)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="56.928" y="12">Vehicle Cream N=1194</tspan>
        <tspan x="3.842" y="31">Maximum Severity during Treatment</tspan>
        <tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed">
            <tspan x="141.662" y="50"></tspan>
        </tspan>
    </text>
    <text id="Trunk" transform="translate(355 2419)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="6.052" y="12">Trunk</tspan>
    </text>
    <text id="N_1202" data-name="N=1202" transform="translate(540.775 2419)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="25.416" y="12">N=1202</tspan>
    </text>
    <text id="N_1185" data-name="N=1185" transform="translate(882.675 2419)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="25.854" y="12">N=1185</tspan>
    </text>
    <text id="Erythema_Scaling_Dryness" data-name="Erythema Scaling Dryness" transform="translate(350 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="3.478" y="12">Erythema</tspan>
        <tspan x="3.478" y="33">Scaling</tspan>
        <tspan x="6.286" y="59.5">Dryness</tspan>
    </text>
    <text id="_26.5_29.7_32.9_26.1_" data-name="26.5% 29.7% 32.9% 26.1%" transform="translate(431.231 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="27.479" y="12">26.5%</tspan>
        <tspan x="27.479" y="36.5">29.7%</tspan>
        <tspan x="27.479" y="61">32.9%</tspan>
        <tspan x="27.479" y="85.5">26.1%</tspan>
    </text>
    <text id="_18.9_13.7_16.1_10.9_" data-name="18.9% 13.7% 16.1% 10.9%" transform="translate(546.408 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="26.207" y="12">18.9%</tspan>
        <tspan x="26.207" y="36.5">13.7%</tspan>
        <tspan x="26.207" y="61">16.1%</tspan>
        <tspan x="26.207" y="85.5">10.9%</tspan>
    </text>
    <text id="_5.2_1.7_1.8_4.3_" data-name="5.2% 1.7% 1.8% 4.3%" transform="translate(664.113 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="19.655" y="12">5.2%</tspan>
        <tspan x="19.655" y="36.5">1.7%</tspan>
        <tspan x="19.655" y="61">1.8%</tspan>
        <tspan x="19.655" y="85.5">4.3%</tspan>
        <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed">
            <tspan x="37.887" y="110"></tspan>
        </tspan>
    </text>
    <text id="_12.7_13.2_17.8_9.2_" data-name="12.7% 13.2% 17.8% 9.2%" transform="translate(780.817 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="12.207" y="12">12.7%</tspan>
        <tspan x="12.207" y="36.5">13.2%</tspan>
        <tspan x="12.207" y="61">17.8%</tspan>
        <tspan x="16.655" y="85.5">9.2%</tspan>
    </text>
    <text id="_4.4_2.6_3.9_2.2_" data-name="4.4% 2.6% 3.9% 2.2%" transform="translate(903.45 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="19.585" y="12">4.4%</tspan>
        <tspan x="19.585" y="36.5">2.6%</tspan>
        <tspan x="19.585" y="61">3.9%</tspan>
        <tspan x="19.585" y="85.5">2.2%</tspan>
        <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed">
            <tspan x="37.817" y="110"></tspan>
        </tspan>
    </text>
    <text id="_0.4_0.1_0.1_0.5_" data-name="0.4% 0.1% 0.1% 0.5%" transform="translate(1014.225 2452)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="20.655" y="12">0.4%</tspan>
        <tspan x="20.655" y="36.5">0.1%</tspan>
        <tspan x="20.655" y="61">0.1%</tspan>
        <tspan x="20.655" y="85.5">0.5%</tspan>
        <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed">
            <tspan x="38.887" y="110"></tspan>
        </tspan>
    </text>
    <text id="Mild_30.6_37.5_39_35.6_" data-name="Mild 30.6% 37.5% 39% 35.6%" transform="translate(445.231 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="20.163" y="12">Mild</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="13.479" y="36.5">30.6%</tspan>
            <tspan x="13.479" y="61">37.5%</tspan>
            <tspan x="20.151" y="85.5">39%</tspan>
            <tspan x="13.479" y="110">35.6%</tspan>
        </tspan>
    </text>
    <text id="Moderate_28.4_27.1_29.7_20.6_" data-name="Moderate 28.4% 27.1% 29.7% 20.6%" transform="translate(558.408 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="0.325" y="12">Moderate</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="13.207" y="36.5">28.4%</tspan>
            <tspan x="13.207" y="61">27.1%</tspan>
            <tspan x="13.207" y="85.5">29.7%</tspan>
            <tspan x="13.207" y="110">20.6%</tspan>
        </tspan>
    </text>
    <text id="Severe_6.2_4.9_4.8_5.9_" data-name="Severe 6.2% 4.9% 4.8% 5.9%" transform="translate(664.113 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="12.641" y="12">Severe</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="20.655" y="36.5">6.2%</tspan>
            <tspan x="20.655" y="61">4.9%</tspan>
            <tspan x="20.655" y="85.5">4.8%</tspan>
            <tspan x="20.655" y="110">5.9%</tspan>
        </tspan>
    </text>
    <text id="Mild_21_23.7_29.9_15.9_" data-name="Mild 21% 23.7% 29.9% 15.9%" transform="translate(782.817 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="17.891" y="12">Mild </tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="17.879" y="36.5">21%</tspan>
            <tspan x="11.207" y="61">23.7%</tspan>
            <tspan x="11.207" y="85.5">29.9%</tspan>
            <tspan x="11.207" y="110">15.9%</tspan>
        </tspan>
    </text>
    <text id="Moderate_6.8_5.9_6.8_3.8_" data-name="Moderate 6.8% 5.9% 6.8% 3.8%" transform="translate(898.45 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="2.325" y="12">Moderate </tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="19.655" y="36.5">6.8%</tspan>
            <tspan x="19.655" y="61">5.9%</tspan>
            <tspan x="19.655" y="85.5">6.8%</tspan>
            <tspan x="19.655" y="110">3.8%</tspan>
        </tspan>
        <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="37.887" y="134.5"></tspan>
        </tspan>
    </text>
    <text id="Severe_0.8_0.3_0.8_0.5_" data-name="Severe 0.8% 0.3% 0.8% 0.5%" transform="translate(1013.225 2270)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan fill="#000">
            <tspan x="13.141" y="12">Severe</tspan>
        </tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="21.155" y="36.5">0.8%</tspan>
            <tspan x="21.155" y="61">0.3%</tspan>
            <tspan x="21.155" y="85.5">0.8%</tspan>
            <tspan x="21.155" y="110">0.5%</tspan>
        </tspan>
        <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="39.387" y="134.5"></tspan>
        </tspan>
    </text>
    <g id="Group_8" data-name="Group 8" transform="translate(256 112.552)">
        <g id="Group_7" data-name="Group 7" transform="translate(685 3565)">
            <path id="Path_1" data-name="Path 1" d="M1579.236,217.91v-8.536h1.158l4.484,6.7v-6.7h1.082v8.536H1584.8l-4.483-6.708v6.708Z" transform="translate(-1561.508 -179.45)" fill="#1a1818" fill-rule="evenodd"/>
            <path id="Path_2" data-name="Path 2" d="M1596.794,236.306a3.406,3.406,0,0,0,.83,2.431,2.9,2.9,0,0,0,4.182-.007,3.631,3.631,0,0,0,.823-2.545,4.353,4.353,0,0,0-.353-1.82,2.688,2.688,0,0,0-1.032-1.205,2.767,2.767,0,0,0-1.523-.428,2.881,2.881,0,0,0-2.061.823A3.673,3.673,0,0,0,1596.794,236.306Zm-1.166-.016a4.637,4.637,0,0,1,1.143-3.329,3.878,3.878,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.13.565,3.691,3.691,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.5,2.29,5.036,5.036,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.251,4.251,0,0,1-2.071.526,4.039,4.039,0,0,1-2.156-.581,3.766,3.766,0,0,1-1.437-1.591A4.808,4.808,0,0,1,1595.628,236.29Z" transform="translate(-1524.35 -128.707)" fill="#1a1818" fill-rule="evenodd"/>
            <path id="Path_3" data-name="Path 3" d="M1586.016,233.194a3.409,3.409,0,0,0,.833,2.43,2.9,2.9,0,0,0,4.182-.007,3.628,3.628,0,0,0,.82-2.545,4.355,4.355,0,0,0-.35-1.82,2.686,2.686,0,0,0-1.032-1.205,2.774,2.774,0,0,0-1.522-.428,2.891,2.891,0,0,0-2.064.823A3.683,3.683,0,0,0,1586.016,233.194Zm-1.163-.016a4.656,4.656,0,0,1,1.14-3.329,3.886,3.886,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.133.565,3.707,3.707,0,0,1,1.447,1.575,5.14,5.14,0,0,1,.5,2.29,5.079,5.079,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.254,4.254,0,0,1-2.074.526,4.035,4.035,0,0,1-2.153-.582,3.741,3.741,0,0,1-1.437-1.591A4.8,4.8,0,0,1,1584.854,233.178Zm-8.49,4.155V228.8h1.13v3.505h4.436V228.8h1.13v8.533h-1.13v-4.021h-4.436v4.021Z" transform="translate(-1568.019 -135.762)" fill="#1a1818" fill-rule="evenodd"/>
            <path id="Path_4" data-name="Path 4" d="M1649.673,221.226v-8.539h1.131v3.508h4.433v-3.508h1.131v8.539h-1.131V217.2H1650.8v4.025Zm-8.771-4.142a3.425,3.425,0,0,0,.836,2.431,2.888,2.888,0,0,0,4.174-.007,3.612,3.612,0,0,0,.824-2.545,4.212,4.212,0,0,0-.356-1.82,2.724,2.724,0,0,0-1.019-1.205,2.968,2.968,0,0,0-3.587.4A3.673,3.673,0,0,0,1640.9,217.083Zm-1.167-.016a4.637,4.637,0,0,1,1.144-3.329,3.886,3.886,0,0,1,2.946-1.2,4.127,4.127,0,0,1,2.136.565,3.69,3.69,0,0,1,1.438,1.575,5.106,5.106,0,0,1,.5,2.29,4.961,4.961,0,0,1-.526,2.326,3.52,3.52,0,0,1-1.486,1.552,4.237,4.237,0,0,1-2.064.526,4.061,4.061,0,0,1-2.163-.582,3.851,3.851,0,0,1-1.437-1.591A4.938,4.938,0,0,1,1639.735,217.067Z" transform="translate(-1424.367 -172.281)" fill="#1a1818" fill-rule="evenodd"/>
            <path id="Path_5" data-name="Path 5" d="M1635.386,207.521a3.424,3.424,0,0,0,.836,2.43,2.885,2.885,0,0,0,4.175-.01,3.586,3.586,0,0,0,.823-2.542,4.361,4.361,0,0,0-.343-1.82,2.731,2.731,0,0,0-2.555-1.633,2.9,2.9,0,0,0-2.064.823A3.684,3.684,0,0,0,1635.386,207.521Zm-1.166-.016a4.639,4.639,0,0,1,1.143-3.329,3.889,3.889,0,0,1,2.947-1.2,4.147,4.147,0,0,1,2.139.565,3.73,3.73,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.493,2.293,4.952,4.952,0,0,1-.529,2.323,3.521,3.521,0,0,1-1.473,1.548,4.291,4.291,0,0,1-2.077.529,4.071,4.071,0,0,1-2.16-.581,3.806,3.806,0,0,1-1.437-1.591A4.906,4.906,0,0,1,1634.22,207.505Z" transform="translate(-1436.871 -193.956)" fill="#1a1818" fill-rule="evenodd"/>
            <line id="Line_26" data-name="Line 26" y1="10.85" x2="7.094" transform="translate(25.528 16.38)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_27" data-name="Line 27" x1="13.158" y1="16.38" transform="translate(19.464 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_28" data-name="Line 28" x1="19.464" y2="7.436" transform="translate(0 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_29" data-name="Line 29" x2="1.049" y2="20.849" transform="translate(0 7.436)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_30" data-name="Line 30" x2="13.262" y2="3.61" transform="translate(1.05 28.284)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_31" data-name="Line 31" x1="0.038" y2="20.825" transform="translate(39.292 44.214)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_32" data-name="Line 32" x1="0.029" y2="16.499" transform="translate(43.044 46.369)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_33" data-name="Line 33" x2="18.013" y2="10.319" transform="translate(39.292 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_34" data-name="Line 34" y1="10.201" x2="18.198" transform="translate(57.304 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_35" data-name="Line 35" y1="8.078" x2="14.414" transform="translate(57.324 62.963)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_36" data-name="Line 36" x1="0.092" y1="20.926" transform="translate(75.41 44.231)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_37" data-name="Line 37" x1="18.164" y1="10.466" transform="translate(57.247 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_38" data-name="Line 38" x1="14.389" y1="8.291" transform="translate(57.258 38.127)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_39" data-name="Line 39" x1="17.917" y2="10.449" transform="translate(39.33 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_40" data-name="Line 40" x1="11.108" y1="6.407" transform="translate(28.222 37.807)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_41" data-name="Line 41" x1="18.011" y2="10.557" transform="translate(21.281 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_42" data-name="Line 42" x1="17.99" y2="10.557" transform="translate(3.291 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_43" data-name="Line 43" x2="10.554" y2="17.938" transform="translate(21.281 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_44" data-name="Line 44" x1="10.588" y1="17.977" transform="translate(10.693 57.619)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_45" data-name="Line 45" x2="17.887" y2="10.406" transform="translate(75.503 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_46" data-name="Line 46" x1="0.037" y2="20.824" transform="translate(147.335 44.286)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_47" data-name="Line 47" x1="0.037" y2="16.475" transform="translate(151.081 46.449)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_48" data-name="Line 48" x2="18.277" y2="10.32" transform="translate(147.335 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_49" data-name="Line 49" y1="10.335" x2="17.933" transform="translate(165.612 65.096)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_50" data-name="Line 50" y1="8.194" x2="14.211" transform="translate(165.599 62.947)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_51" data-name="Line 51" x1="0.086" y1="20.927" transform="translate(183.458 44.168)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_52" data-name="Line 52" x1="18.031" y1="10.332" transform="translate(165.428 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_53" data-name="Line 53" x1="14.297" y1="8.19" transform="translate(165.428 38.152)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_54" data-name="Line 54" x1="18.056" y2="10.45" transform="translate(147.372 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_55" data-name="Line 55" x1="17.884" y2="10.423" transform="translate(129.452 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_56" data-name="Line 56" x1="17.931" y1="10.238" transform="translate(111.52 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_57" data-name="Line 57" x1="14.217" y1="8.118" transform="translate(111.513 69.571)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_58" data-name="Line 58" x1="18.13" y2="10.267" transform="translate(93.39 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_59" data-name="Line 59" x1="0.034" y2="20.91" transform="translate(93.355 75.563)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_60" data-name="Line 60" x1="0.028" y2="16.526" transform="translate(97.123 77.759)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_61" data-name="Line 61" x2="18.151" y2="10.321" transform="translate(93.355 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_62" data-name="Line 62" y1="10.343" x2="17.896" transform="translate(111.507 96.451)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_63" data-name="Line 63" y1="8.204" x2="14.201" transform="translate(111.492 94.3)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_64" data-name="Line 64" y1="20.917" x2="0.049" transform="translate(129.402 75.533)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_65" data-name="Line 65" x1="11.951" y2="7.085" transform="translate(81.404 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_66" data-name="Line 66" x1="12.176" y1="6.943" transform="translate(57.195 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_67" data-name="Line 67" x1="17.938" y2="10.442" transform="translate(39.257 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_68" data-name="Line 68" x1="11.791" y1="6.59" transform="translate(27.466 100.478)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_69" data-name="Line 69" y1="10.394" x2="18.08" transform="translate(183.458 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_70" data-name="Line 70" x2="11.951" y2="6.947" transform="translate(201.538 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_71" data-name="Line 71" y1="14.196" x2="0.025" transform="translate(199.672 20.653)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            <line id="Line_72" data-name="Line 72" y1="14.2" x2="0.025" transform="translate(203.405 20.659)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
        </g>
    </g>
    <g id="Group_20" data-name="Group 20">
        <text id="_Means_presented_in_table_are_Least_Square_LS_means" data-name="*Means presented in table are Least Square (LS) means" transform="translate(336 5530.997)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="12">*Means presented in table are Least Square (LS) means</tspan>
        </text>
        <g id="Group_16" data-name="Group 16">
            <text id="Table_3._Acne_of_the_Face_Efficacy_Results_at_Week_12_Intent-to-Treat_Multiple_Imputation_" data-name="Table 3. Acne of the Face Efficacy Results at Week 12 (Intent-to-Treat; Multiple Imputation)" transform="translate(336 5229)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="0" y="12">Table 3. Acne of the Face Efficacy Results at Week 12 (Intent-to-Treat; Multiple Imputation)</tspan>
            </text>
            <g id="Group_9" data-name="Group 9" transform="translate(337.625 5253)">
                <rect id="Rectangle_3" data-name="Rectangle 3" width="1000" height="266.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_73" data-name="Line 73" x2="1000" transform="translate(0 203.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_74" data-name="Line 74" x2="1000" transform="translate(0 139.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_75" data-name="Line 75" x2="1000" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_76" data-name="Line 76" x2="670.5" transform="translate(330.875 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_77" data-name="Line 77" y2="239.257" transform="translate(839.813 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_78" data-name="Line 78" y2="266.233" transform="translate(686.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_79" data-name="Line 79" y2="239.257" transform="translate(522.188 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_80" data-name="Line 80" y2="266.233" transform="translate(330.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
            </g>
            <text id="IGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="IGA Success At least a 2-grade improvement and “Clear” (0) or “Almost Clear” (1)" transform="translate(351.625 5337.919)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan fill="#000">
                    <tspan x="65.546" y="12">IGA Success</tspan>
                </tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="1.391" y="31">At least a 2-grade improvement and</tspan>
                    <tspan x="21.703" y="50"> “Clear” (0) or “Almost </tspan>
                </tspan>
            </text>
            <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Inflammatory Lesions Mean* Absolute (Percent)  Change from Baseline" transform="translate(351.625 5399.919)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="31.479" y="12">Inflammatory Lesions</tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="22.279" y="31">Mean* Absolute (Percent) </tspan>
                    <tspan x="34.727" y="50">Change from Baseline</tspan>
                </tspan>
            </text>
            <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Non-inflammatory Lesions Mean* Absolute (Percent) Change from Baseline" transform="translate(370.625 5461.919)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="26.718" y="12">Non-inflammatory Lesions</tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="30.936" y="31">Mean* Absolute (Percent)</tspan>
                    <tspan x="38.279" y="50">Change from Baseline</tspan>
                </tspan>
            </text>
            <text id="Study_1" data-name="Study 1" transform="translate(856.983 5271.337)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="-28.895" y="0">Study 1</tspan>
            </text>
            <text id="Study_2" data-name="Study 2" transform="translate(1177.577 5271.337)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="-28.895" y="0">Study 2</tspan>
            </text>
            <text id="AKLIEF_Cream_N_612_" data-name="AKLIEF Cream (N= 612)" transform="translate(715 5285.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="5.694" y="12">AKLIEF Cream</tspan>
                <tspan x="22.518" y="31">(N=600) </tspan>
            </text>
            <text id="Vehicle_Cream_N_596_" data-name="Vehicle Cream (N= 596)" transform="translate(868 5285.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="20.582" y="12">Vehicle Cream</tspan>
                <tspan x="35.518" y="31">(N= 596)</tspan>
            </text>
            <text id="AKLIEF_Cream_N_602_" data-name="AKLIEF Cream (N= 602)" transform="translate(1030.245 5285.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="19.694" y="12">AKLIEF Cream</tspan>
                <tspan x="37.518" y="31">(N=602)</tspan>
            </text>
            <text id="Vehicle_Cream_N_610_" data-name="Vehicle Cream (N=610)" transform="translate(1181 5285.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="20.582" y="12">Vehicle Cream</tspan>
                <tspan x="35.518" y="31">(N=610)</tspan>
            </text>
            <text id="_29.4_-19.0_-54.4_-25.0_-49.7_" data-name="29.4% -19.0 (-54.4%) -25.0 (-49.7%)" transform="translate(715 5348)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">29.4%</tspan>
                <tspan x="5.142" y="85">-19.0 (-54.4%)</tspan>
                <tspan x="5.142" y="149">-25.0 (-49.7%)</tspan>
            </text>
            <text id="_19.5_-15.4_-44.8_-17.9_-35.7_" data-name="19.5% -15.4 (-44.8%) -17.9 (-35.7%)" transform="translate(898 5348)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">19.5%</tspan>
                <tspan x="0" y="85">-15.4 (-44.8%)</tspan>
                <tspan x="0" y="149">-17.9 (-35.7%)</tspan>
            </text>
            <text id="_42.3_-24.2_-66.2_-30.1_-57.7_" data-name=" 42.3% -24.2 (-66.2%) -30.1 (-57.7%)" transform="translate(1051.245 5348)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="21.47" y="12" xml:space="preserve"> 42.3%</tspan>
                <tspan x="0" y="85">-24.2 (-66.2%)</tspan>
                <tspan x="0" y="149">-30.1 (-57.7%)</tspan>
            </text>
            <text id="_25.7_-18.7_-51.2_-21.6_-43.9_" data-name=" 25.7% -18.7 (-51.2%) -21.6 (-43.9%)" transform="translate(1200 5348)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="21.47" y="12" xml:space="preserve"> 25.7%</tspan>
                <tspan x="0" y="85">-18.7 (-51.2%)</tspan>
                <tspan x="0" y="149">-21.6 (-43.9%)</tspan>
            </text>
        </g>
    </g>
    <g id="Group_19" data-name="Group 19">
        <text id="_Means_presented_in_table_are_Least_Square_LS_means-2" data-name="*Means presented in table are Least Square (LS) means" transform="translate(336 5880.997)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="12">*Means presented in table are Least Square (LS) means</tspan>
        </text>
        <g id="Group_18" data-name="Group 18" transform="translate(0 404)">
            <g id="Group_9-2" data-name="Group 9" transform="translate(337.625 5194)">
                <rect id="Rectangle_3-2" data-name="Rectangle 3" width="1000" height="266.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_73-2" data-name="Line 73" x2="1000" transform="translate(0 203.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_74-2" data-name="Line 74" x2="1000" transform="translate(0 139.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_75-2" data-name="Line 75" x2="1000" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_76-2" data-name="Line 76" x2="670.5" transform="translate(330 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_77-2" data-name="Line 77" y2="239.257" transform="translate(839.813 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_78-2" data-name="Line 78" y2="266.233" transform="translate(686.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_79-2" data-name="Line 79" y2="239.257" transform="translate(522.188 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_80-2" data-name="Line 80" y2="266.233" transform="translate(330.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
            </g>
            <text id="PGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="PGA Success At least a 2-grade improvement and “Clear” (0) or “Almost Clear” (1)" transform="translate(370.625 5271.919)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan fill="#000">
                    <tspan x="62.433" y="12">PGA Success</tspan>
                </tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="1.391" y="31">At least a 2-grade improvement and</tspan>
                    <tspan x="21.703" y="50">“Clear” (0) or “Almost </tspan>
                </tspan>
            </text>
            <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Inflammatory Lesions Mean* Absolute (Percent) Change from Baseline" transform="translate(375.625 5338.919)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="31.479" y="12">Inflammatory Lesions</tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="22.279" y="31">Mean* Absolute (Percent) </tspan>
                    <tspan x="34.727" y="50">Change from Baseline</tspan>
                </tspan>
            </text>
            <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Non-inflammatory Lesions Mean* Absolute (Percent) Change from Baseline" transform="translate(370.625 5401.919)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="26.718" y="12">Non-inflammatory Lesions</tspan>
                <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                    <tspan x="30.936" y="31">Mean* Absolute (Percent)</tspan>
                    <tspan x="38.279" y="50">Change from Baseline </tspan>
                </tspan>
            </text>
            <text id="Study_1-2" data-name="Study 1" transform="translate(856.983 5212.337)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="-28.895" y="0">Study 1</tspan>
            </text>
            <text id="Study_2-2" data-name="Study 2" transform="translate(1177.577 5212.337)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
                <tspan x="-28.895" y="0">Study 2</tspan>
            </text>
            <text id="AKLIEF_Cream_N_600_" data-name="AKLIEF Cream (N= 600)" transform="translate(715 5231.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="5.694" y="12">AKLIEF Cream</tspan>
                <tspan x="22.518" y="31">(N=600)</tspan>
            </text>
            <text id="Vehicle_Cream_N_585_" data-name="Vehicle Cream (N= 585)" transform="translate(868 5231.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="20.582" y="12">Vehicle Cream</tspan>
                <tspan x="22.518" y="31">(N=585)</tspan>
            </text>
            <text id="AKLIEF_Cream_N_598_" data-name="AKLIEF Cream (N= 598)" transform="translate(1030.245 5231.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="19.694" y="12">AKLIEF Cream</tspan>
                <tspan x="22.518" y="31">(N=598)</tspan>
            </text>
            <text id="Vehicle_Cream_N_609_" data-name="Vehicle Cream (N=609)" transform="translate(1181 5231.47)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="20.582" y="12">Vehicle Cream</tspan>
                <tspan x="22.518" y="31">(N=609)</tspan>
            </text>
            <text id="_35.7_-21.4_-57.4_-21.9_-49.1_" data-name="35.7% -21.4 (-57.4%) -21.9 (-49.1%)" transform="translate(715 5300)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">35.7%</tspan>
                <tspan x="0" y="71">-21.4 (-57.4%)</tspan>
                <tspan x="0" y="149">-21.9 (-49.1%)</tspan>
            </text>
            <text id="_25.0_-18.8_-50.0_-17.8_-40.3_" data-name="25.0% -18.8 (-50.0%) -17.8 (-40.3%)" transform="translate(898 5300)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">25.0%</tspan>
                <tspan x="0" y="71">-18.8 (-50.0%)</tspan>
                <tspan x="0" y="149">-17.8 (-40.3%)</tspan>
            </text>
            <text id="_42.6_-25.5_-65.4_-25.9_-55.2_" data-name="42.6% -25.5 (-65.4%) -25.9 (-55.2%)" transform="translate(1051.245 5300)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">42.6%</tspan>
                <tspan x="0" y="71">-25.5 (-65.4%)</tspan>
                <tspan x="0" y="149">-25.9 (-55.2%)</tspan>
            </text>
            <text id="_29.9_-19.8_-51.1_-20.8_-45.1_" data-name="29.9% -19.8 (-51.1%) -20.8 (-45.1%)" transform="translate(1200 5300)" fill="#1a1818" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="23.694" y="12">29.9%</tspan>
                <tspan x="0" y="71">-19.8 (-51.1%)</tspan>
                <tspan x="0" y="149">-20.8 (-45.1%)</tspan>
            </text>
        </g>
        <text id="Table_4._Acne_of_the_Trunk_Efficacy_Results_at_Week_12_Intent-to-Treat_on_the_Trunk_Multiple_Imputation_" data-name="Table 4. Acne of the Trunk Efficacy Results at Week 12 (Intent-to-Treat on the Trunk; Multiple Imputation)" transform="translate(337.625 5571.487)" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="12">Table 4. Acne of the Trunk Efficacy Results at Week 12 (Intent-to-Treat on the Trunk; Multiple Imputation)</tspan>
        </text>
    </g>
    <line id="Line_89" data-name="Line 89" x2="1000" transform="translate(336 592.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
    <line id="Line_90" data-name="Line 90" x2="1000" transform="translate(336 958.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
    <g id="Group_4" data-name="Group 4" transform="translate(338 2245.643)">
        <path id="Path_6" data-name="Path 6" d="M0-30.049H766v350.2H0Z" transform="translate(0 0)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_6" data-name="Line 6" x2="766" transform="translate(0 271.823)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_7" data-name="Line 7" x2="766" transform="translate(0 247.491)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_8" data-name="Path 8" d="M3.281,8.012H772.563" transform="translate(-3.281 214.752)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_9" data-name="Line 9" x2="766" transform="translate(0 195.012)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_10" data-name="Line 10" x2="766" transform="translate(0 67.273)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_10" data-name="Path 10" d="M0,0H766" transform="translate(0 163.349)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_12" data-name="Line 12" x2="766" transform="translate(0 118.61)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_13" data-name="Line 13" x2="766" transform="translate(0 92.87)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_14" data-name="Line 14" x2="766" transform="translate(0 41.092)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_7" data-name="Path 7" d="M2.816-17.01h766" transform="translate(0 32.331)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_16" data-name="Line 16" y2="125" transform="translate(659.225 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_17" data-name="Line 17" y2="148.027" transform="translate(656.225 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_18" data-name="Line 18" y2="125" transform="translate(541.143 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_19" data-name="Line 19" y2="148.027" transform="translate(541.143 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_20" data-name="Line 20" y2="350" transform="translate(425.714 -30.143)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_9" data-name="Path 9" d="M-17.208-38.222v125" transform="translate(327.286 233.079)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_22" data-name="Line 22" y2="148.027" transform="translate(310.286 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_23" data-name="Line 23" x1="0.357" y2="125" transform="translate(197.5 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_24" data-name="Line 24" y2="148.027" transform="translate(197.857 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_25" data-name="Line 25" x1="0.275" y2="350" transform="translate(90.5 -30.143)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
    </g>
</g>
<text id="Important:_AKLIEF_Cream_is_for_use_on_the_skin_only._Do_not_use_AKLIEF_Cream_in_your_mouth_eyes_or_vagina._What_is_AKLIEF_Cream_AKLIEF_Cream_is_a_prescription_medicine_used_on_the_skin_topical_to_treat_acne_vulgaris_in_people_9_years_of_age_and_olde" class="desktop" data-name="Important: AKLIEF Cream is for use on the skin only.  Do not use AKLIEF Cream in your mouth, eyes, or vagina.What is AKLIEF Cream? AKLIEF Cream is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 9 years of age and olde" transform="translate(-131 6486)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
    <tspan x="0" y="12">Important:</tspan>
    <tspan y="12" xml:space="preserve" font-family="Helvetica-Light, Helvetica" font-weight="300"> AKLIEF Cream is for use on the skin only.  Do not use AKLIEF Cream in your mouth, eyes, or vagina.</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="50"></tspan>
    </tspan>
    <tspan x="0" y="69">What is AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="88">AKLIEF Cream is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 9 years of age and older.</tspan>
        <tspan x="0" y="107">It is not known if AKLIEF Cream is safe and effective in children younger than 9 years old.</tspan>
        <tspan x="0" y="145"></tspan>
    </tspan>
    <tspan x="0" y="145">Before using AKLIEF Cream, tell your healthcare provider about all of your medical conditions, including if you:</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="164" xml:space="preserve">•   have skin problems, including eczema, cuts or sunburn</tspan>
        <tspan x="0" y="183" xml:space="preserve">•   are pregnant or planning to become pregnant. It is not known if AKLIEF Cream will harm your unborn baby.</tspan>
        <tspan x="0" y="202" xml:space="preserve">•   are breastfeeding or plan to breastfeed. It is not known if AKLIEF Cream passes into your breast milk. Breastfeeding women should use </tspan>
        <tspan x="0" y="221" xml:space="preserve">     AKLIEF Cream on the smallest area of skin and for the shortest time needed while breastfeeding. Do not apply AKLIEF Cream to the nipple</tspan>
        <tspan x="0" y="240" xml:space="preserve">     and areola to avoid contact with your baby.</tspan>
    </tspan>
    <tspan x="0" y="259">Tell your healthcare provider about all the medicines you take,</tspan>
    <tspan y="259" xml:space="preserve" font-family="Helvetica-Light, Helvetica" font-weight="300"> including prescription and over-the-counter medicines, vitamins and </tspan>
    <tspan x="0" y="278" font-family="Helvetica-Light, Helvetica" font-weight="300">herbal supplements.</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="297">Especially tell your healthcare provider if you use any other medicine for acne.</tspan>
    </tspan>
    <tspan x="0" y="337">How should I use AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="356" xml:space="preserve">•   Use AKLIEF Cream exactly as your healthcare provider tells you to use it. Apply a thin layer of AKLIEF Cream over the affected areas 1 time</tspan>
        <tspan x="0" y="375" xml:space="preserve">     each day, in the evening.</tspan>
    </tspan>
    <tspan x="0" y="394">Applying AKLIEF Cream:</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="413" xml:space="preserve">•   Wash the area where the cream will be applied and pat dry.</tspan>
        <tspan x="0" y="432" xml:space="preserve">•   If you receive a sample tube of AKLIEF Cream, follow your healthcare provider’s instructions about how much to apply.</tspan>
        <tspan x="0" y="451" xml:space="preserve">•   AKLIEF Cream comes in a pump.</tspan>
        <tspan x="0" y="470" xml:space="preserve">    -   Press down on (depress) the pump 1 time to dispense a small amount of AKLIEF Cream and spread a thin layer over your face</tspan>
        <tspan x="0" y="489" xml:space="preserve">         (forehead, cheeks, nose, and chin). Avoid contact with your eyes, lips, mouth, and the corners of your nose.</tspan>
        <tspan x="0" y="508" xml:space="preserve">    -   Press down on the pump 2 times to dispense enough AKLIEF Cream to apply a thin layer to cover your upper trunk (the area of your </tspan>
        <tspan x="0" y="527" xml:space="preserve">         upper back that you can reach, shoulders, and chest). One more pump may be used to apply a thin layer of AKLIEF Cream to your </tspan>
        <tspan x="0" y="546" xml:space="preserve">         middle and lower back, if acne is present.</tspan>
        <tspan x="0" y="565" xml:space="preserve">•   When you begin treatment with AKLIEF Cream, you should begin applying a moisturizer on your skin as often as needed.</tspan>
        <tspan y="565" font-family="Helvetica-Bold, Helvetica" font-weight="700">See “Local skin </tspan>
    </tspan>
    <tspan x="0" y="584" xml:space="preserve">     irritation”</tspan>
    <tspan y="584" xml:space="preserve" font-family="Helvetica-Light, Helvetica" font-weight="300"> below.</tspan>
 
    <tspan x="0" y="604">What should I avoid while using AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="623" xml:space="preserve">•   Minimize exposure to sunlight. You should avoid using sunlamps, tanning beds, and ultraviolet light during treatment with AKLIEF Cream. </tspan>
        <tspan x="0" y="642" xml:space="preserve">     If you have to be in sunlight or are sensitive to sunlight, use a sunscreen with a SPF (sun protection factor) of 15 or more, and wear</tspan>
        <tspan x="0" y="661" xml:space="preserve">     protective clothing and a wide-brimmed hat to cover the treated areas.</tspan>
        <tspan x="0" y="680" xml:space="preserve">•   Avoid using AKLIEF Cream on skin areas with cuts, abrasions, eczema, or on sunburned skin.</tspan>
        <tspan x="0" y="699" xml:space="preserve">•   Avoid using skin products that may dry or irritate your skin, such as: </tspan>
        <tspan x="0" y="718" xml:space="preserve">    -   medicated or abrasive soaps and cleansers</tspan>
        <tspan x="0" y="737" xml:space="preserve">    -   soaps, cleansers, and cosmetics that have strong skin drying effects</tspan>
        <tspan x="0" y="756" xml:space="preserve">    -   products that contain high amounts of alcohol</tspan>
        <tspan x="0" y="775">• Avoid the use of “waxing” as a hair removal method on skin treated with AKLIEF Cream.</tspan>
    </tspan>
    <tspan x="0" y="815">What are the possible side effects of AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="834">AKLIEF Cream may cause serious side effects including:</tspan>
        <tspan x="0" y="853" xml:space="preserve">•   </tspan>
        <tspan y="853" font-family="Helvetica-Bold, Helvetica" font-weight="700">Local skin irritation.</tspan>
        <tspan y="853" xml:space="preserve"> Local skin reactions are common with AKLIEF Cream, are most likely to happen during the first 4 weeks of treatment </tspan>
        <tspan x="0" y="872" xml:space="preserve">     and may decrease with continued use of AKLIEF Cream. Signs and symptoms of local skin reactions include:</tspan>
        <tspan x="0" y="891" xml:space="preserve">    -   redness		- dryness</tspan>
        <tspan x="0" y="910" xml:space="preserve">    -   scaling		- stinging or burning</tspan>
        <tspan x="0" y="929" xml:space="preserve">     To help reduce your risk of developing these local skin reactions, when you begin treatment with AKLIEF Cream, you should begin applying</tspan>
        <tspan x="0" y="958" xml:space="preserve">     a moisturizer on your skin as often as needed.</tspan>
        <tspan x="0" y="977" xml:space="preserve">     Tell your healthcare provider if you develop symptoms of a local skin reaction. Your doctor may tell you to use AKLIEF Cream less often, or </tspan>
        <tspan x="0" y="996" xml:space="preserve">     temporarily, or permanently stop your treatment with AKLIEF Cream.</tspan>
        <tspan x="0" y="1015" xml:space="preserve">     The most common side effects of AKLIEF Cream include: itching and sunburn. </tspan>
        <tspan y="1015" font-family="Helvetica-Bold, Helvetica" font-weight="700">See “What should I avoid while using AKLIEF Cream”.</tspan>
        <tspan x="0" y="1034" xml:space="preserve">     These are not all the possible side effects of AKLIEF Cream. For more information, ask your healthcare provider or pharmacist.</tspan>
        <tspan x="0" y="1053" xml:space="preserve">     Callyour doctor formedical advice about side eects. You mayreport side eects to FDA at 1-800-FDA-1088.</tspan>
        <tspan x="0" y="1072" xml:space="preserve">     You may also report side eects to GALDERMA LABORATORIES, L.P. at 1-866-735-4137</tspan>
    </tspan>
    <tspan x="0" y="1112">How should I store AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="1131" xml:space="preserve">• Store AKLIEF Cream at room temperature, 68° to 77°F(20° to 25°C).</tspan>
        <tspan x="0" y="1150" xml:space="preserve"> • Keep AKLIEF Cream awayfrom heat.</tspan>
        <tspan x="0" y="1169" xml:space="preserve"> • If you receive a sample tube of AKLIEF Cream from your healthcare provider, keep the tube tightlyclosed.</tspan>
    </tspan>
        <tspan x="0" y="1188">Keep AKLIEF Cream and all medicines out of the reach of children.</tspan>

    <tspan x="0" y="1228">General information about the safe and eective use of AKLIEF Cream.</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="1247" xml:space="preserve">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use AKLIEF Cream for a</tspan>
        <tspan x="0" y="1266" xml:space="preserve">condition for which it was not prescribed. Do not give AKLIEF Cream to other people, even if they have the same symptomsyou have. It may</tspan>
        <tspan x="0" y="1285" xml:space="preserve">harm them. You can askyour pharmacist or healthcare provider for information about AKLIEF Cream that is written for health professionals.</tspan>
    </tspan>

    <tspan x="0" y="1325">What are the ingredientsin AKLIEF Cream?</tspan>
    <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="1344" font-family="Helvetica-Bold, Helvetica" font-weight="700">Active ingredient:</tspan>
        <tspan y="1344" xml:space="preserve">trifarotene</tspan>
        <tspan x="0" y="1363" font-family="Helvetica-Bold, Helvetica" font-weight="700">Inactive ingredients:</tspan>
        <tspan y="1363" xml:space="preserve">allantoin,copolymer of acrylamide and sodium acryloyldimethyltaurate, dispersion 40% in isohexadecane,</tspan>
        <tspan x="0" y="1382" xml:space="preserve">cyclomethicone, 5% ethanol, medium-chain triglycerides, phenoxyethanol, propylene glycol, purified water.</tspan>
    </tspan>
    </text>
  <line id="Line_91" data-name="Line 91" x2="1000" transform="translate(-131 6415.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
  <text id="Patient_Information_AKLIEF_trifarotene_cream" data-name="Patient Information AKLIEF® (trifarotene) cream" transform="translate(0.25 6434)" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
    <tspan x="311.109" y="12">Patient Information </tspan>
    <tspan x="276.309" y="31">AKLIEF® (trifarotene) cream</tspan></text>
</svg>


<svg xmlns="http://www.w3.org/2000/svg"  class="mobile" width="376" height="32" viewBox="0 0 376 32">
    <text id="HIGHLIGHTS_OF_PRESCRIBING_INFORMATION" data-name="HIGHLIGHTS OF PRESCRIBING INFORMATION" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="9.48" y="12">HIGHLIGHTS OF PRESCRIBING INFORMATION</tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="342" height="525" viewBox="0 0 342 525">
    <text id="These_highlights_do_not_include_all_the_information_needed_to_use_AKLIEF_Cream_safely_and_effectively._See_full_prescribing_information_for_AKLIEF_Cream._AKLIEF_trifarotene_cream_for_topical_use_Initial_U.S._Approval:_2019_-_INDICATIONS_AND_U" data-name="These highlights do not include all the information needed to use AKLIEF® Cream safely and effectively. See full prescribing information for AKLIEF Cream. AKLIEF (trifarotene) cream, for topical use Initial U.S. Approval: 2019 ————-—————INDICATIONS AND U" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">These highlights do not include all the </tspan>
        <tspan x="0" y="31">information needed to use AKLIEF</tspan>
        <tspan y="31" font-size="9.333" baseline-shift="5.33279994943018">®</tspan>
        <tspan y="31" xml:space="preserve"> Cream </tspan>
        <tspan x="0" y="50">safely and effectively. See full prescribing </tspan>
        <tspan x="0" y="69">information for AKLIEF Cream.</tspan>
        <tspan x="0" y="88">AKLIEF (trifarotene) cream, for topical use</tspan>
        <tspan x="0" y="107">Initial U.S. Approval: 2019</tspan>
        <tspan x="0" y="126"></tspan>
        <tspan x="0" y="145">————-—————INDICATIONS AND </tspan>
        <tspan x="0" y="164">USAGE————————-</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="183">AKLIEF Cream is a retinoid indicated for the </tspan>
            <tspan x="0" y="202">topical treatment of acne vulgaris in patients 9 </tspan>
            <tspan x="0" y="221">years of age and older. (1)</tspan>
        </tspan>
        <tspan x="0" y="240"></tspan>
        <tspan x="0" y="259">—————-——DOSAGE AND </tspan>
        <tspan x="0" y="278">ADMINISTRATION———————</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="297" xml:space="preserve">•   For topical use only. Not for oral, ophthalmic </tspan>
            <tspan x="0" y="316">or </tspan><tspan x="0" y="335" xml:space="preserve">     intravaginal use.</tspan>
            <tspan x="0" y="354" xml:space="preserve">•   Apply a thin layer of AKLIEF Cream to the </tspan>
            <tspan x="0" y="373" xml:space="preserve">affected areas of        </tspan>
            <tspan x="0" y="392" xml:space="preserve">     the face and/or trunk once a day, in the </tspan>
            <tspan x="0" y="411">evening, on clean </tspan>
            <tspan x="0" y="430" xml:space="preserve">     and dry skin. Avoid contact with the eyes, </tspan>
            <tspan x="0" y="449">lips, paranasal </tspan>
            <tspan x="0" y="468" xml:space="preserve">     creases, and mucous membranes. (2)</tspan>
        </tspan>
        <tspan x="0" y="487"></tspan>
        <tspan x="0" y="506">———————DOSAGE FORMS AND </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" width="342" height="421" class="mobile" viewBox="0 0 342 421">
    <text id="_Skin_irritation:_Erythema_scaling_dryness_and_stinging_burning_may_be_experienced_with_use_of_AKLIEF_Cream._Use_a_moisturizer_from_the_initiation_of_treat ent_and_if_appropriate_reduce_the_frequency_of_application_of_AKLIEF_" data-name="•   Skin irritation: Erythema, scaling, dryness, and stinging/ burning may be experienced with use of AKLIEF Cream.   Use a moisturizer from the initiation of treatment, and, if  appropriate, reduce the frequency of application of AKLIEF " font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12" xml:space="preserve">•   Skin irritation: Erythema, scaling, dryness, </tspan>
        <tspan x="0" y="31">and stinging/</tspan><tspan x="0" y="50" xml:space="preserve">     burning may be experienced with use of </tspan>
        <tspan x="0" y="69">AKLIEF Cream. </tspan><tspan x="0" y="88" xml:space="preserve">     Use a moisturizer from the initiation of </tspan>
        <tspan x="0" y="107">treatment, and, if </tspan>
        <tspan x="0" y="126" xml:space="preserve">     appropriate, reduce the frequency of </tspan>
        <tspan x="0" y="145">application of AKLIEF </tspan>
        <tspan x="0" y="164" xml:space="preserve">     Cream, suspend or discontinue use. (5.1)</tspan>
        <tspan x="0" y="183" xml:space="preserve">•   Ultraviolet Light and Environmental </tspan>
        <tspan x="0" y="202">Exposure: Minimize </tspan>
        <tspan x="0" y="221" xml:space="preserve">     exposure to sunlight and sunlamps. Use </tspan>
        <tspan x="0" y="240">sunscreen and </tspan>
        <tspan x="0" y="259" xml:space="preserve">     protective clothing over treated areas when </tspan>
        <tspan x="0" y="278">exposure </tspan>
        <tspan x="0" y="297" xml:space="preserve">     cannot be avoided. (5.2)</tspan>
        <tspan font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="0" y="316"></tspan>
            <tspan x="0" y="335">—————-————ADVERSE REACTIONS</tspan>
            <tspan x="0" y="354">——————————</tspan>
        </tspan>
        <tspan x="0" y="373">Most common adverse reactions (incidence ≥ </tspan>
        <tspan x="0" y="392">1%) in patients treated with AKLIEF Cream </tspan>
        <tspan x="0" y="411">were application site irritation, application site </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="432" height="38" viewBox="0 0 432 38">
  <text id="FULL_PRESCRIBING_INFORMATION:_CONTENTS_" data-name="FULL PRESCRIBING INFORMATION: CONTENTS*" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700"><tspan x="27.848" y="12">FULL PRESCRIBING INFORMATION: CONTENTS*</tspan></text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="343" height="293" viewBox="0 0 343 293">
    <text id="_1_INDICATIONS_AND_USAGE_2_DOSAGE_AND_ADMINISTRATION_3_DOSAGE_FORMS_AND_STRENGTHS_4_CONTRAINDICATIONS_5_WARNINGS_AND_PRECAUTIONS_5.1_Skin_Irritation_5.2_Ultravio et_Light_and_Environmental_Exposure_6_ADVERSE_REACTIONS_6.1_Clinical_Trials_Experie" data-name="1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Skin Irritation  5.2 Ultraviolet Light and Environmental Exposure 6 ADVERSE REACTIONS 6.1 Clinical Trials Experie" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">1 INDICATIONS AND USAGE</tspan>
        <tspan x="0" y="31">2 DOSAGE AND ADMINISTRATION</tspan>
        <tspan x="0" y="50">3 DOSAGE FORMS AND STRENGTHS</tspan>
        <tspan x="0" y="69">4 CONTRAINDICATIONS</tspan>
        <tspan x="0" y="88">5 WARNINGS AND PRECAUTIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="107" xml:space="preserve">    5.1 Skin Irritation</tspan>
            <tspan x="0" y="126" xml:space="preserve">    5.2 Ultraviolet Light and Environmental </tspan>
            <tspan x="0" y="145">Exposure</tspan>
        </tspan>
        <tspan x="0" y="164">6 ADVERSE REACTIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="183" xml:space="preserve">    6.1 Clinical Trials Experience</tspan>
        </tspan>
        <tspan x="0" y="202">7 DRUG INTERACTIONS</tspan>
        <tspan x="0" y="221">8 USE IN SPECIFIC POPULATIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="240" xml:space="preserve">    8.1 Pregnancy</tspan>
            <tspan x="0" y="259" xml:space="preserve">    8.2 Lactation</tspan>
            <tspan x="0" y="278" xml:space="preserve">    8.4 Pediatric Use</tspan>
        </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="340" height="246" viewBox="0 0 340 246">
    <text id="_11_DESCRIPTION_12_CLINICAL_PHARMACOLOGY_12.1_Mechanism_of_Action_12.2_Pharmacodynamics_12.3_Pharmacokinetics_13_NONCLINICAL_TOXICOLOGY_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_14_CLINICAL_STUDIES_16_HOW_SUPPLIED_STORAGE_AND" data-name="11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics  12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">11 DESCRIPTION</tspan>
        <tspan x="0" y="31">12 CLINICAL PHARMACOLOGY</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="50" xml:space="preserve">    12.1 Mechanism of Action</tspan>
            <tspan x="0" y="69" xml:space="preserve">    12.2 Pharmacodynamics</tspan>
            <tspan x="0" y="88" xml:space="preserve">    12.3 Pharmacokinetics</tspan>
        </tspan>
        <tspan x="0" y="107">13 NONCLINICAL TOXICOLOGY</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="126" xml:space="preserve">    13.1 Carcinogenesis, Mutagenesis, </tspan>
            <tspan x="0" y="145">Impairment of Fertility</tspan>
        </tspan>
        <tspan x="0" y="164">14 CLINICAL STUDIES</tspan>
        <tspan x="0" y="183">16 HOW SUPPLIED/STORAGE AND </tspan>
        <tspan x="0" y="202">HANDLING</tspan>
        <tspan x="0" y="221">17 PATIENT COUNSELING INFORMATION</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="240">*Sections or subsections omitted from the</tspan>
        </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="432" height="38" viewBox="0 0 432 38">
  <text id="FULL_PRESCRIBING_INFORMATION" data-name="FULL PRESCRIBING INFORMATION" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700"><tspan x="79.848" y="12">FULL PRESCRIBING INFORMATION</tspan></text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="341" height="1264" viewBox="0 0 341 1264"> 
    <text id="_1_INDICATIONS_AND_USAGE_AKLIEF_Cream_is_a_retinoid_indicated_for_the_topical_treatment_of_acne_vulgaris_in_patients_9_years_of_age_and_older._2_DOSAGE_AND_ADMINISTRATION_Apply_a_thin_layer_of_AKLIEF_Cream_to_the_affected_areas_" data-name="1   INDICATIONS AND USAGE AKLIEF Cream is a retinoid indicated for the topical  treatment of acne vulgaris in patients 9 years of age and  older. 2   DOSAGE AND ADMINISTRATION Apply a thin layer of AKLIEF Cream to the affected areas " font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12" xml:space="preserve">1   INDICATIONS AND USAGE</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="31" xml:space="preserve">     AKLIEF Cream is a retinoid indicated for the </tspan>
            <tspan x="0" y="50">topical </tspan>
            <tspan x="0" y="69" xml:space="preserve">     treatment of acne vulgaris in patients 9 </tspan>
            <tspan x="0" y="88">years of age and </tspan>
            <tspan x="0" y="107" xml:space="preserve">     older.</tspan>
        </tspan>
        <tspan x="0" y="126" xml:space="preserve">2   DOSAGE AND ADMINISTRATION</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="145" xml:space="preserve">     Apply a thin layer of AKLIEF Cream to the </tspan>
            <tspan x="0" y="164">affected areas </tspan>
            <tspan x="0" y="183" xml:space="preserve">     once daily, in the evening, on clean and dry </tspan>
            <tspan x="0" y="202">skin.</tspan>
            <tspan x="0" y="221" xml:space="preserve">     •   One pump actuation should be enough </tspan>
            <tspan x="0" y="240">to cover the face </tspan>
            <tspan x="0" y="259" xml:space="preserve">          (i.e., forehead, cheeks, nose, and chin).</tspan>
            <tspan x="0" y="278" xml:space="preserve">     •   Two actuations of the pump should be </tspan>
            <tspan x="0" y="297">enough to cover </tspan>
            <tspan x="0" y="316" xml:space="preserve">          the upper trunk (i.e., reachable upper </tspan>
            <tspan x="0" y="335">back, shoulders </tspan>
            <tspan x="0" y="354" xml:space="preserve">          and chest). One additional pump </tspan>
            <tspan x="0" y="373">actuation may be used </tspan>
            <tspan x="0" y="392" xml:space="preserve">          for middle and lower back if acne is </tspan>
            <tspan x="0" y="411">present.</tspan>
            <tspan x="0" y="430" xml:space="preserve">     The use of a moisturizer is recommended as </tspan>
            <tspan x="0" y="449" xml:space="preserve">frequently as  </tspan>
            <tspan x="0" y="468" xml:space="preserve">     needed from the initiation of treatment.</tspan>
            <tspan x="0" y="487" xml:space="preserve">     Avoid contact with the eyes, lips, paranasal </tspan>
            <tspan x="0" y="506">creases,</tspan>
            <tspan x="0" y="525" xml:space="preserve">     mucous membranes.</tspan>
            <tspan x="0" y="544" xml:space="preserve">     AKLIEF Cream is for topical use only. Not for </tspan>
            <tspan x="0" y="563">oral,</tspan>
            <tspan x="0" y="582" xml:space="preserve">     ophthalmic, or intravaginal use.</tspan>
        </tspan>
        <tspan x="0" y="601" xml:space="preserve">3   DOSAGE FORMS AND STRENGTHS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="620" xml:space="preserve">     Cream: 0.005%. Each gram of AKLIEF </tspan>
            <tspan x="0" y="639">Cream contains 50 </tspan>
            <tspan x="0" y="658" xml:space="preserve">     mcg of trifarotene in a white cream.</tspan>
        </tspan>
        <tspan x="0" y="677" xml:space="preserve">4   CONTRAINDICATIONS</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="696" xml:space="preserve">     None</tspan>
        </tspan>
        <tspan x="0" y="715" xml:space="preserve">5   WARNINGS AND PRECAUTIONS</tspan>
        <tspan x="0" y="734" xml:space="preserve">     5.1   Skin Irritation</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="753" xml:space="preserve">     Patients using AKLIEF Cream may </tspan>
            <tspan x="0" y="772">experience erythema, </tspan>
            <tspan x="0" y="791" xml:space="preserve">     scaling, dryness, and stinging/burning. </tspan>
            <tspan x="0" y="810">Maximum severity </tspan>
            <tspan x="0" y="829" xml:space="preserve">     of these reactions typically occurred within </tspan>
            <tspan x="0" y="848">the first 4 weeks </tspan>
            <tspan x="0" y="867" xml:space="preserve">     of treatment, and severity decreased with </tspan>
            <tspan x="0" y="886">continued use of </tspan>
            <tspan x="0" y="905" xml:space="preserve">     the medication. Depending upon the </tspan>
            <tspan x="0" y="924">severity of these </tspan>
            <tspan x="0" y="943" xml:space="preserve">     adverse reactions, instruct patients to use a </tspan>
            <tspan x="0" y="962">moisturizer, </tspan>
            <tspan x="0" y="981" xml:space="preserve">     reduce the frequency of application of </tspan>
            <tspan x="0" y="1000">AKLIEF Cream, or </tspan>
            <tspan x="0" y="1019" xml:space="preserve">     suspend use temporarily. If severe reactions </tspan>
            <tspan x="0" y="1038">persist the </tspan>
            <tspan x="0" y="1057" xml:space="preserve">     treatment may be discontinued.</tspan>
            <tspan x="0" y="1076" xml:space="preserve">     Avoid application of AKLIEF Cream to cuts, </tspan>
            <tspan x="0" y="1095">abrasions, or </tspan>
            <tspan x="0" y="1114" xml:space="preserve">     eczematous or sunburned skin. Use of </tspan>
            <tspan x="0" y="1133">“waxing” as a </tspan>
            <tspan x="0" y="1152" xml:space="preserve">     depilatory method should be avoided on </tspan>
            <tspan x="0" y="1171">skin treated with </tspan>
            <tspan x="0" y="1190" xml:space="preserve">     AKLIEF Cream.</tspan>
        </tspan>
        <tspan x="0" y="1209" xml:space="preserve">     5.2   Ultraviolet Light and Environmental </tspan>
        <tspan x="0" y="1228">Exposure</tspan>
        <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
            <tspan x="0" y="1247" xml:space="preserve">     Minimize unprotected exposure to ultraviolet </tspan>
        </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="341" height="65" viewBox="0 0 341 65">
    <text id="Table_1._Adverse_Reactions_Occurring_in_1.0_of_Subjects_with_Acne_Vulgaris_of_the_Face_and_Trunk_in_the_Two_12-week_Phase_3_Clinical_Trials" data-name="Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face and Trunk in the Two 12-week Phase 3 Clinical Trials" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700">
        <tspan x="0" y="12">Table 1. Adverse Reactions Occurring in ≥ </tspan>
        <tspan x="0" y="31">1.0% of Subjects with Acne Vulgaris of the </tspan>
        <tspan x="0" y="50">Face and Trunk in the Two 12-week Phase 3 </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="345.24" height="108.201" viewBox="0 0 345.24 108.201">
    <g id="Group_28" data-name="Group 28" transform="translate(-16.76 -3052.383)">
        <g id="Group_1" data-name="Group 1" transform="translate(17 3052.623)">
            <rect id="Rectangle_1" data-name="Rectangle 1" width="340.858" height="107.721" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_1" data-name="Line 1" x2="340.858" transform="translate(0 80.791)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_2" data-name="Line 2" x2="340.858" transform="translate(0 53.861)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_3" data-name="Line 3" x2="340.858" transform="translate(0 26.93)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_4" data-name="Line 4" y2="107.721" transform="translate(227.239)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            <line id="Line_5" data-name="Line 5" y2="107.721" transform="translate(113.619)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
        </g>
        <text id="Preferred_Term_Application_site_irritation_Application_site_pruritus_Sunburn" data-name="Preferred Term Application site irritation Application site pruritus Sunburn" transform="translate(17 3056.335)" fill="#1a1818" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="13.974" y="9">Preferred Term</tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="15.205" y="35">Application site </tspan>
                <tspan x="35.215" y="61">irritation</tspan>
                <tspan x="15.205" y="87">Application site </tspan>
            </tspan>
        </text>
        <text id="AKLIEF_Cream_N_1220_91_7.5_29_2.4_32_2.6_" data-name="AKLIEF Cream (N= 1220) 91 (7.5) 29 (2.4) 32 (2.6)" transform="translate(130.548 3056.335)" fill="#1a1818" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="3.215" y="9">AKLIEF Cream (N= </tspan>
            <tspan x="41.38" y="35">1220)</tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="36.05" y="61">91 (7.5)</tspan>
                <tspan x="36.05" y="87">29 (2.4)</tspan>
            </tspan>
        </text>
        <text id="Vehicle_Cream_N_1200_4_0.3_10_0.8_6_0.5_" data-name="Vehicle Cream (N=1200) 4 (0.3) 10 (0.8) 6 (0.5)" transform="translate(244 3056.335)" fill="#1a1818" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="17.524" y="9">Vehicle Cream </tspan>
            <tspan x="33.371" y="35">(N=1200)</tspan>
            <tspan font-family="Helvetica-Light, Helvetica" font-weight="300">
                <tspan x="41.211" y="61">4 (0.3)</tspan>
                <tspan x="37.875" y="87">10 (0.8)</tspan>
            </tspan>
        </text>
    </g>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="344" height="543" viewBox="0 0 344 543">
    <text id="Additional_adverse_reactions_that_were_reported_in_more_than_one_subject_treated_with_AKLIEF_Cream_and_at_a_frequency_1_included_application_site_pain_application_site_dryness_application_site_discoloration_application_site_rash_application_site_sw" data-name="Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included application site pain, application site dryness, application site discoloration, application site rash, application site sw" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300">
        <tspan x="0" y="12">Additional adverse reactions that were reported </tspan>
        <tspan x="0" y="31">in more than one subject treated with AKLIEF </tspan>
        <tspan x="0" y="50">Cream (and at a frequency &lt;1%) included </tspan>
        <tspan x="0" y="69">application site pain, application site dryness, </tspan>
        <tspan x="0" y="88">application site discoloration, application site </tspan>
        <tspan x="0" y="107">rash, application site swelling, application site </tspan>
        <tspan x="0" y="126">erosion, acne, dermatitis allergic, and </tspan>
        <tspan x="0" y="145">erythema.</tspan>
        <tspan x="0" y="164"></tspan>
        <tspan x="0" y="183">In the one-year, open-label safety trial that </tspan>
        <tspan x="0" y="202">included 453 subjects 9 years and older, with </tspan>
        <tspan x="0" y="221">acne vulgaris of the face and trunk, the pattern </tspan>
        <tspan x="0" y="240">of adverse reactions for AKLIEF Cream was </tspan>
        <tspan x="0" y="259">similar to that experienced in the 12-week </tspan>
        <tspan x="0" y="278">controlled trials. A total of 12.6% of subjects </tspan>
        <tspan x="0" y="297">had at least one adverse reaction during the </tspan>
        <tspan x="0" y="316">trial, and 2.9% of subjects had an adverse </tspan>
        <tspan x="0" y="335">reaction leading to treatment discontinuation. </tspan>
        <tspan x="0" y="354">The most common adverse reactions (≥ 1% of </tspan>
        <tspan x="0" y="373">subjects) for the entire trial were application site </tspan>
        <tspan x="0" y="392">pruritus (4.6%), application site irritation (4.2%), </tspan>
        <tspan x="0" y="411">and sunburn (5.5%). The frequency of adverse </tspan>
        <tspan x="0" y="430">reactions decreased over time.</tspan>
        <tspan x="0" y="449"></tspan>
        <tspan x="0" y="468">Skin irritation was evaluated by active </tspan>
        <tspan x="0" y="487">assessment of erythema, scaling, dryness, and </tspan>
        <tspan x="0" y="506">stinging/burning and collected separately. In </tspan>
        <tspan x="0" y="525">the two 12-week Phase 3 clinical trials, these </tspan>
    </text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="328" height="49" viewBox="0 0 328 49">
  <text id="Table_2._Application_Site_Tolerability_Reactions_at_Any_Post_Baseline_Visit" data-name="Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit" fill="#1a1818" font-size="16" font-family="Helvetica-Bold, Helvetica" font-weight="700" letter-spacing="-0.01em">
    <tspan x="0" y="12">Table 2. Application Site Tolerability </tspan><tspan x="0" y="31">Reactions at Any Post Baseline Visit</tspan></text>
</svg>
<svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="337.676" height="322.67" viewBox="0 0 337.676 322.67">
    <path id="Path_6" data-name="Path 6" d="M0-30.049H337.176v322.17H0Z" transform="translate(0.25 30.299)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
    <svg xmlns="http://www.w3.org/2000/svg" class="mobile" width="74" height="25" viewBox="0 0 74 25">
        <text id="Face" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700"><tspan x="22.987" y="9">Face</tspan></text>
    </svg>
    <svg xmlns="http://www.w3.org/2000/svg" width="0.5" height="322" viewBox="0 0 0.5 322">
        <line id="Line_25" data-name="Line 25" y2="322" transform="translate(0.25)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
    </svg>
    <svg xmlns="http://www.w3.org/2000/svg" width="128" height="50" viewBox="100 0 128 50">
        <text id="AKLIEF_Cream_N_1214_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1214 Maximum Severity during Treatment" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="21.654" y="9">AKLIEF Cream </tspan>
            <tspan x="42.478" y="21">N=1214</tspan>
            <tspan x="10.972" y="33">Maximum Severity </tspan>
            <tspan x="14.655" y="45">during Treatment</tspan>
        </text>
    </svg>
    <svg xmlns="http://www.w3.org/2000/svg" width="128" height="50" viewBox="0 0 128 50">
        <text id="AKLIEF_Cream_N_1194_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1194 Maximum Severity during Treatment" font-size="12" font-family="Helvetica-Bold, Helvetica" font-weight="700">
            <tspan x="21.654" y="9">AKLIEF Cream </tspan>
            <tspan x="42.806" y="21">N=1194</tspan>
            <tspan x="10.972" y="33">Maximum Severity </tspan>
            <tspan x="14.655" y="45">during Treatment</tspan>
        </text>
    </svg>

    <svg xmlns="http://www.w3.org/2000/svg" width="336.711" height="0.5" viewBox="0 0 336.711 0.5">
        <path id="Path_7" data-name="Path 7" d="M2.816-17.01H339.527" transform="translate(-2.816 17.26)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
    </svg>

</svg>









<svg xmlns="http://www.w3.org/2000/svg" width="768" height="180" viewBox="0 0 768 180">
  <text id="Marketed_by:_GALDERMA_LABORATORIES_L.P._Fort_Worth_Texas_76177_USA_All_trademarks_are_the_property_of_their_respective_owners._Made_in_Canada_This_Patient_Information_has_been_approved_by_the_U.S._Food_and_Drug_Administration._Issued:_10_2019_P54485-" data-name="Marketed by:
GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA
All trademarks are the property of their respective owners.
Made in Canada

This Patient Information has been approved by the U.S. Food and Drug Administration. 
Issued: 10/2019

P54485-" font-size="16" font-family="Helvetica-Light, Helvetica" font-weight="300"><tspan x="0" y="12">Marketed by:</tspan><tspan x="0" y="31">GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA</tspan><tspan x="0" y="50">All trademarks are the property of their respective owners.</tspan><tspan x="0" y="69">Made in Canada</tspan><tspan x="0" y="88"></tspan><tspan x="0" y="107">This Patient Information has been approved by the U.S. Food and Drug Administration. </tspan><tspan x="0" y="126">Issued: 10/2019</tspan><tspan x="0" y="145"></tspan><tspan x="0" y="164">P54485-1</tspan></text>
</svg>
</div>
</div>
